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I. ABSTRACT 
Inactivation of p53, a tumor suppressor gene, contributes to the genesis and/or 
progression of a substantial fraction of human cancers, including over 50% of breast, 
lung and colon carcinomas. To elucidate the role of p53 inactivation in the genesis of 
prostatic carcinoma and hyperplasia, we examined 18 human prostatic carcinomas and 
30 hyperplasias for p53 protein by immunohistochemistry, allelic loss around or at the 
p53 gene by hybridization analyses, p53 gene mutation by Polymerase Chain Reaction 
-Single Stranded Conformation Polymorphism (PCR-SSCP) analysis plus direct DNA 
sequencing and human papillomavirus (HPV) infection by PGR method. 
Immunohistochemical staining performed in frozen prostatic carcinoma using 
monoclonal antibodies PAB240 and DOT showed p53 protein nuclear accumulation in 
7 and 5 out of 17 cancers respectively. When using microwave treated paraffin 
embedded cancer tissue sections, 12 of these cases demonstrated p53 accumulation with 
D07 in cancer cells. No staining was seen in the hyperplastic samples except some 
nuclei of prostatic basal cells. Allelic loss at 17pl3.3 around the p53 gene was detected 
only in one cases of prostatic carcinoma out of 12 informative cancers and this same 
case was the only one to reveal allelic loss ofHa-ras oncogene (1/4 informative cases). 
Of the 5 and 11 informative cases of respectively, prostatic carcinoma and hyperplasia, 
none demonstrated allelic loss at p53 gene. No allelic loss at the locus on the long arm 
of chromosome 17 was observed in 9 informative cases (5 cancers and 4 hyperplasias). 
PCR-SSCP analyses plus direct DNA sequencings on exons 4-8 of p53 gene premitted 
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detection in one case of prostatic carcinoma with mutation in exon 5 (CGC to CAC 
at codon 175) and in two examples of prostatic hyperplasia with mutation in exon 4 
(GCT to GTT at codon 63) and intron 6 (G to C at 17 base pairs downstream of 3， 
end of exon 6). These two base pair variations in hyperplastic tissue were suggested 
to be a rare polymorphism in this population. Finally, by PGR method, no samples was 
detected to be infected by HPV. 
These findings in prostatic carcinoma indicate the lack of relationship between 
protein accumulation as demonstrated by p53 immunohistochemistry, allelic loss and 
mutation of p53 in prostatic carcinoma examined by hybridization and PCR-SSCP 
analysis. p53 protein accumulation frequently occurred in prostatic carcinoma but p53 
allelic loss and mutation were uncommon events in this cancer. Moreover, p53 




II. 1 Epidemiology of prostate cancer 
Prostate cancer is the second most frequent cause of cancer death in males in 
most countries of the Western world such as the United States, causing 9 to 11 % of 
all cancer deaths every year (1,2,3). This death rate is exceeded only by lung cancer, 
and is followed by deaths from gastrointestinal tumors (1,2,3,4). Although lung cancer 
is also the first leading cancer death in males in Hong Kong as in most Western 
countries, prostate cancer in Hong Kong is excluded in the list of ten leading cancer 
deaths (Table 1，next page) (5). Annually, prostate cancer causes less than 0.9 % of all 
cancer deaths in Hong Kong and thus representing a ten-fold difference from the 
Western world (5). Moreover, the relatively high occurrence of prostate cancer among 
Americans (42 per 100 000 males per year) shows a marked contrast with that of Hong 
Kong Chinese (5.6 per 100 000 males per year) (1,2,3,4,5,6). The differences in the 
incidence and mortality rates of prostate cancer between two regions have not been 
specifically studied and the causes of such differences remain uncertain, but the role 
of genetic and environmental factors may be suggested (1,2,3,4,6). The ethnic 
difference (Caucasians versus Chinese) cannot fully explain the disparity in the 
incidence and mortality rate of this cancer. The study of migrants of one ethnic origin 
living in another country can help differentiate between environmental and genetic 
factors. If the incidence and mortality rates of the migrants verge toward the rates of 
the host country, this provides evidence for an environmental influence (2,3). If, on the 
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Table 1 ： Ten leading cancer deaths in males in Hong Kong (1987 to 1989) 
Disease Group 87 88 89 
1.Malignant neoplasm of trachea, bronchus and lung 1609 1500 1731 
2.Malignant neoplasm of liver and intrhepatic bile ducts 820 877 859 
3.Malignant neoplasm of stomach 316 317 376 
4.Malignant neoplasm of nasopharynx 329 341 338 
5. Malignant neoplasm of oesophagus 310 317 313 
6. Malignant neoplasm of colon 267 269 300 
7. Malignant neoplasm of rectosigmoid junction and anus 145 143 168 
8. Malignant neoplasm of pancreas 120 119 121 
9. Malignant neoplasm of bladder 125 123 114 
10. Leukaemia 111 112 107 
Prostate cancer 77 60 77 
source : Hong Kong Department of Health (Annual Departmental Report 91-92) 
\\ 
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other hand, the incidence remains similar to that of the country of origin, a genetic 
factor is favored (2,3). The incidence of prostate cancer in native Japanese is 4 per 100 
000 whereas for those living in the United States, it is between 12 and 21 per 100 000 
and for those in Hawaii 36 per 100 000. This data may demonstrate that prostate 
carcinogenesis can be directly affected by environmental factors (2,3,6,7,8). 
Epidemiological studies from various authors demonstrated the effect and the 
relationship of many factors to prostate cancer. Men with more pre- and extramarital 
partners, more sexual drive, more frequent coitus and history of sexual transmitted 
disease were found to be correlated with higher risk of prostate cancer (2,3,4). Diet had 
also been shown to be correlated to the incidence of prostate cancer (2,3). There is a 
positive association of high fat, beef, milk products and eggs with prostate cancer and 
a negative association with green and yellow vegetables (2,3). Heavy vitamin A intake 
also seems to be related to this cancer (2,3). The difference in incidence and mortality 
rate of prostate cancer between Americans and Hong Kong Chinese may possibly be 
related to the difference in sexual behaviour and dietary habits. 
While differences in incidence and mortality rate of prostate cancer between 
Americans and Hong Kong Chinese are marked, men under the age of 50 from both 
regions rarely have prostate cancer. Table 2 (next page) depicts the demographic data 
of patients with prostate cancer and hyperplasia compended at the Prince of Wales 
Hospital during the period between 1985 and 1992. At Prince of Wales Hospital, only 
2 cases of prostate cancer in men below age 50 were found between 1985 and 1992 
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Table 2: 
Age <30 31-40 41-50 51-60 61-70 >70 
CaP 2 0 0 14 44 96 
BPH 5 3 U 156 523 648 
Total 7 3 14 170 567 744 
Total no. of CaP in PWH = 156 Total no. of BPH in PWH= 1349 
Average age for CaP: 71.4 Average age for BPH: 69.8 
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(eight years), with a total of 156 cancer of prostate and 1349 transurethral 
prostatectomies during the same period (Table 2, page 6). After the age of 50, the 
number of new cases of prostate cancer increases at an almost constant exponential rate 
(Figure 1, next page). The average age of patients with prostate cancer in The Prince 
of Wales Hospital from 1985 to 1992 is 71.4 (Table 2, page 6). Similarly to prostate 
cancer, benign prostatic hyperplasia is also relatively rare below the age of 50 (21 out 
of 1349) during the same period in this institution. Moreover, the exponential increase 
in the number of new cases of benign prostatic hyperplasia also occurs after the age 
of 50 (Figure 2，page 9). The average age of patients with benign prostatic hyperplasia 
during these eight years was 69.8 (Table 2，page 6). Therefore, as expected these two 
diseases are affecting the elderly population. 
Table 3 (page 10) shows the yearly number of new cases of prostate cancer 
diagnosed in Hong Kong during the period between 1981 and 1989. An increasing 
incidence of prostate cancer is observed in this institution, although a similar increase 
in the rate of admission in hospital is also observed (Figure 3, page 11). However, the 
rising incidence seems to be genuine when the percentage is examined. This increase 
incidence over the past ten years may represent an interesting observation. While true 
increase in incidence can be partly explained by changing and improvement of 
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diagnostic practices, this may also reflect by the epidemiology of changes in the sexual 
behaviors and dietary habits mentioned above. Over the past several decades, the 
influence of Western culture on the Hong Kong Chinese population may have directly 
modified sexual behaviors (promiscous practice) and dietary habits (high consumption 
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Table 3 ： No. of new cancer cases per year in Hong Kong 
Year 81 82 83 84 85 86 87 88 89 
CaP 110 109 149 154 173 NA 162 219 209 
Total 11088 11986 13156 13330 14423 NA 14527 15255 16464 
cancers 
(NA- not avariable) 
source: Hong Kong Hospital Services Department (Annual Departmental Reports 84-89) 
Hong Kong Department of Health (Annual Departmental Reports 89-93) ' 
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of fat, milk products and eggs). This changing of lifestyle may represent the 
environmental variable attributable to the rise of prostatic cancer in Hong Kong. 
Cancers are thought to develop as a result of several sequential genetic events, 
occurring stepwise over time, which may involve activation of oncogenes or 
inactivation of tumor suppressor genes (7,8,9). Tumor suppressor genes are now known 
to play an important role in the development of a wide variety of human cancers 
(9，10,11). The p53 gene is a tumor suppressor gene and its mutations have been 
identified in colon and breast adenocarcinomas, small cell and non-small cell 
carcinomas of the lung, and brain tumors (12,13,14). The p53 immunohistochemistry 
is frequently employed to investigate the importance of p53 gene in the tumorigenesis 
according to the currently accepted concepts that p53 gene mutations lead to 
accumulation of highly stabilized p53 mutant proteins which can be detected using 
monoclonal antibody immunohistochemical technique (15). The incidence of p53 
immunoreactivity in lung and colon carcinoma has been found to be 60 to 70 % while 
it is lower in breast and ovarian carcinomas (14’ 15,16,17，18). 
Despite the high prevalence of prostate cancer in the Western countries 
including the United States and the second leading cause of cancer mortality, very little 
is known regarding the molecular mechanisms involved in prostate tumorigenesis. 
Studies of oncogenes and suppressor genes in prostate carcinoma are still at its early 
stages and reports on the subject remain relatively limited. This work has been aimed 
at examining the role of p53 suppressor gene in prostate carcinoma. Studies of p53 
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suppressor gene in atypical hyperplasia and benign hyperplasia were also carried on 
and attempted to identify a possible relationship between prostatic lesions. 
II.2. Anatomy of the human prostate 
The human prostate is a chestnut like organ, with its base lying immediately 
below the bladder neck and surrounding the proximal portion of the urethra and its 
apex sitting on the deep layer of the urogenital diagram. The puboprostatic ligaments 
attach to the anterior to maintain its position. The broad, flattened triangular posterior 
surface which lies anterior to the rectum, contains a longitudinal midline depression 
called the median sulcus. 
Prostatic urethra is divided into proximal and distal segments of approximately 
equal length by an abrupt anterior angulation of its posterior wall at the mid-point 
between prostate apex and bladder neck. The angle of deviation is roughly 35°, but it 
is quite variable and is greater in men with nodular hyperplasia (BPH). At the point 
of angulation, there are a projection, verumontanum, from the posterior urethral wall 
and a pair of ejaculatory ducts extending proximally from the urethra to the base of 
the prostate. �� 
The prostate is composed of one nonglandular and three different glandular 
zones. The largest is the peripheral zone, which contains 70% of all glandular tissues, 
followed by the central zone with 25%, and the transition zone with 5%. Anteriorly, 
a nonglandular zone contains fibromuscular stroma. Prostatic glands are concentrated 
13 
in the peripheral zone and are lined by a single layer of columnar secretory cells and 
are infolded into the lumen to give a pseudopapillary pattern. Surrounding these 
secretory units is a layer of inconspicuous basal cells; these are not myoepithelial cells 
and are presumed to be the precursors of the secretory cells. 
The prostate receives blood from a branch of the internal iliac artery via the 
inferior vesical artery. The venous drainage of the gland empties into the prevertebral 
plexus and the hypogastric venous system. Lymphatic drainage occurs through the 
external and internal iliac as well as obturator lymph nodes. Innervation occurs through 
both sympathetic and parasympathetic fibers. 
Growth and development of the prostate are hormone dependent and need the 
tropic action of both oestrogens and androgens. The prostate is immature at birth and 
only grows to its normal size at puberty when androgen secretion commences. 
11.3. Pathology of prostate diseases 
Prostatic Hyperplasia (synonyms: nodular hyperplasia, "BPH" or benign 
prostatic hypertrophy or hyperplasia, adenomatous hypertrophy, glandular and stromal 
hyperplasia) is a very common condition in the aging male associated with enlargement 
of the organ. The pathogenesis of prostatic hyperplasia is poorly understood, however 
involution of the glands associated with an unbalance response to hormonal stimuli 
partly explain this benign condition. The prostatic enlargement is usually nodular and 
its severity depends upon the size. Early lesions occur in the periurethral region and 
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subsequently larger lesions develop laterally. The periurethral nodules cause prostatism, 
clinical manifestations of the disease which includes dysuria, frequency of micturition 
and obstructive symptoms. Pathologically, the hyperplastic nodule consists of both 
smooth muscle stroma and glands (Figure 4, next page), however the proportion of 
stromal and glandular hyperplasia varies widely. Microscopically, acini exhibit 
glandular hyperplasia with papillary infoldings (Figure 5, next page). The epithelium 
consists of tall pale columnar cells overlining a layer of small basal cells (Figure 5, 
next page). The treatment of prostatic hyperplasia is symptomatic and often requires 
surgery. There has been no indication of a relationship between prostatic hyperplasia 
and prostatic carcinoma based on epidemiological studies (2,3,4). 
Atypical Hyperplasia represents the overgrowth of glandular elements 
associated with glandular and cytological atypias. Atypical hyperplasia represents the 
morphological spectrum of prostatic glands that can not be readily classified neither 
as benign hyperplasia nor prostatic carcinoma. Conceptually, atypical hyperplasia may 
be regarded as a morphological transition between benign hyperplasia and carcinoma. 
Such a concept thus represents an attempt to link benign hyperplasia and cancer, but 
lacks support from the absence of clinical relationship between the two diseases. 
Microscopically, atypical hyperplasia is recognized when epithelial proliferations lead 
to filling of acini, expansion of lobules, cribiform pattern or papillary structures. 
Cytological atypia reflects the degree of nuclear differentiation or anaplasia, which 
severity is based on the degree of nuclear crowding, enlargement or nucleolar 
prominence. The biological behavior of atypical hyperplasia depend upon the severity 
15 
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Figure 4: Hyperplastic nodule consisting of enlarged glands with cellular hyperplasia 
耀 
Figure 5: Acini in Prostatic Hyperplasia exhibiting increased number of epithelial cells leading 
to formation of tufts. The cells have preserved uniformity and basal nuclear orientation. 
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of its grading. Low grade lesions are not associated with increased risk of maligancy, 
contrary to the high grade lesions. While the intermediate grade may be associated with 
increase risk of malignancy, but the rate of malignant transformation can not be 
predicted. 
Prostatic Carcinoma. Nearly 98% of prostate cancer comprise carcinoma 
arising from prostatic glandular epithelium and classified as adenocarcinoma. Of these 
rare variant such as small cell carcinoma, transitional cell carcinoma and other 
uncommon types of carcinoma have been reported (19,20). The remaining non-
epithelial cancers are rare and comprises tumours differentiating mostly towards 
smooth or skeletal muscles or other mesenchymal tissues, lymphomas and metastatic 
tumours. The pathogenesis of prostatic carcinoma is incompletely understood and 
several factors have been recognized and incriminated and these include genetic, 
hormonal, environmental and infectious influences (20,21). Carcinomas of prostate tend 
to arise peripherally in the posterior and posterolateral regions and only later involve 
the central zones. The pathological diagnosis of prostatic carcinoma is based on tumour 
cells forming glands with varying degree of differentiation (Figure 6, next page), 
invasion and cytological anaplasia (Figure 7, next page). Grading of prostatic 
carcinoma is important to the assessment of the biological behaviour of the tumours 
and to establish a prognosis (19,20,21,22). Many systems of grading have been 
proposed, and none have overcome the problems of reproducibility and reliability. The 
Gleason grading system is the better recognized and is the one employed in this study 
(21,22,23,24,25). The grading in this study is also supplemented by the WHO 
17 
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Figure 6: Prostatic glands with varying degree of differentiation m Prostatic Carcinoma. 
m 
Figure 7: Cytological anaplasia with prominent nucleoli 
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recommended grading based on the degree of nuclear anaplasia and glandular 
differentiation (22,23,24,25). Staging of prostatic carcinoma is also important in 
prognostication as it estimates the extent of the tumour (20,21,23). Staging is mainly 
based on clinical assessment of the extent of the tumour, but it has also been assessed 
pathologically based on total prostatectomy specimens. 
II.4. Tumor suppressor gene - Human p53 
4.1. General Aspects 
The proliferation of normal cells is thought to be regulated by growth-promoting 
proto-oncogenes counterbalanced by growth-constraining tumor suppressor genes. 
Mutations that potentiate the activities of proto-oncogenes and oncogenes to force the 
growth of tumor cells. Conversely, genetic lesions that inactivate suppressor genes 
liberate the cell from the constraints imposed by these genes, yielding the 
unconstrained growth of the cancer cell (8,9,26,27). 
There are several evidences for the existence of tumor suppressor genes. Early 
evidence came from somatic cell hybridization, which showed that fUsion of tumor 
cells with normal cells almost invariably results in the outgrowth of nontumorigenic 
hybrids (28,29). This indicated that some genetic information capable of suppressing 
A 
the neoplastic phenotype of their tumor cell partners was donated from the normal 
cells. Since the karyotypes of these hybrids were unstable, they frequently shed 
chromosomes originating from one or another parent. When the chromosomes from the 
normal parent were lost, the hybrid cells would often revert back to a tumorigenic 
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state. This led to the conclusion that these chromosomes carried genes that were 
missing from the genomes of tumor cells and could act to normalize the growth 
program of the cancer cells (30). 
Discovery of Rb gene functional loss in the cell genome of the parent with the 
rare childhood eye tumor retinoblastoma by Knudson (31) provided a second clue that 
suggested the existence of tumor suppressor genes. This Rb gene is considered to 
become allied with the tumor suppressor genes uncovered through cell fusion 
experiment. Single inactive Rb alleles act within cells throughout the body in a 
recessive manner, as children who are effectively hemizygous for Rb undergo 
essentially normal development. Only the rare cell that mutation occurs in remaining 
wild-type allele shows evidence of growth deregulation. 
The loss of chromosomal material at certain loci that is characteristic of many 
cancers signals the existence of tumor suppressor genes. No fewer than 12 
chromosomal regions have been implicated in tumor suppression by this criterion 
(Table 4，next page). Several tumor susceptability genes have been identified. They are 
Wtl, Rb, p53, NFl and DCC, located at the chromosomal regions l l p l3 , 13ql4, 
17pl3.1, 17qll.2 and 18q21.3 respectively (32). 
4.2. Human p53 gene - Historical perspectives 
p53 protein was originally discovered in extracts of transformed cells, reacting 
With antiserum from animals with tumors induced by Simian virus 40 (SV40) (33,34). 
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Table 4: Chromosomal deletions associated with cancer 
Chromosomal Associated tumor Type of cancers 
Deletion suppressor gene 
Ip Melanoma, neuroblastoma, medullary thyroid 
carcinoma, pheochromocytoma, ductal breast 
carcinoma 
Iq Breast carcinoma 
3p Small-cell lung carcinoma, renal cell carcinoma, 
cervical carcinoma, von Hippel-Lindau 
disease 
5q Familial adenomatous polyposis sporadic 
colorectal carcinoma 
6q Melanoma 
Up WTl Wilm's tumor, breast carcinoma, rhabdomyo-
"“sarcoma, hepatoblastoma, transitional cell 
bladder carcinoma 
I l lq Multiple endocrine neoplasia 
I 13q Rb Retinoblastoma, osteosarcoma, small-cell 
carcinoma, ductal breast carcinoma 
17p p53 Small-cell lung carcinoa, colorectal carcinoma, 
breast carcinoma, osteosarcoma 
17q NFl Neurofibroma 








The protein was found to form an oligomeric complex in SV40-transformed cells with 
the SV40 oncogene product, the large T antigen (33,34). Because large T antigen is 
needed to maintain the transformed phenotype, it was suggested that this interaction 
• 春 
IS important for transformation. Thus, p53 came to be classified as a tumor antigen. 
The complementary DNA (cDNA) and genomic clones of the p53 gene were 
isolated and characterized (35,36,37,38,39). In the in vitro systems, some p53 cDNA 
clones could immortalize primary rat cells (40,41,42), transform such cells in concert 
with activated ras (43,44), and render nontransformed cells platelet-derived growth 
factor (PDGF)-indepentent (45,46). In addition, p53 expression vectors also exerted in 
vzVo effects: They enhanced tumor formation by weakly tumorigenic cell lines (47,48) 
and increased the metastatic capacity of tumor cells (49). These features were, to a 
large extent, similar to those displayed by myc-overexpressing plasmids and suggested 
that p53 was, in fact, a myc-like oncogene. 
However, all of these transforming p53 cDNA clones turned out to be mutant 
forms of p53 (50). Further, the p53 gene now looks like being a tumor suppressor 
gene, negatively regulating the cell cycle and requiring loss-of-fiinction mutations for 
tumor formation: expression of cDNA or genomic clones of wild-type p53 suppresses 
the transformation of cells in culture by other oncogenes (51,52), the growth of 
transformed cells in cutlure (53,54,55,56), and the tumorigenic potential of cells in 
animals (26); and deletions or mutations of wild-type p53 alleles occur in several 
animal (57) and human (12) tumors. 
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The p53 protein has therefore changed from being classified as a tumor antigen 
to an oncogene product and now to a tumor suppressor. 
4.3. Human p53 gene - Structure 
Highly conservation of p53 gene among varies organisms such as Xenpus laevis 
(58)，chickens (59), and the mouse and human (38,60,61,62) has been demonstrated. 
There are five highly conserved domains: Domain I (codons 13 to 19), Domain II 
(codons 117 to 142), Domain III (codons 171 to 181)，Domain VI (codons 234 to 
258), and Domain V (codons 270 to 286) (58). This suggested that the encoded protein 
plays a central and critical role in the cell and therefore is tightly conserved in 
evolution. 
The p53 gene encompasses about 20 kb of DNA located on the short arm of 
human chromsome 17 at position 17pl3.1 (62). It composed of 11 exons, the first of 
which is noncoding. This first exon contains 213 base pairs and is found about 10 kb 
away from exon 2 to 11. Thus, the first intron comprises about one-half of the gene. 
Several restriction site polymorphism in human p53 gene were revealed. One 
gene polymorphism was the existence of AccII-restriction sites in exon 4 of the p53 
gene. The other gene polymorphism was a BamHI-restriction site, found at the 5' 
region upstream to the first p53 noncoding exon (63,64). A third polymorphic site was 
the Bglll -restriction site in the first noncoding large intron, situated 3 kb downstream 
to the first Bglll site (65). 
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The p53 gene codes for a 2.6 kb messenger RNA (mRNA) molecule that 
contains a large 3，noncoding region probably involved in the stabilization of the 
molecule (38). 
4.4. Human p53 protein - Structure 
Human p53 protein contains 393 amino acids and has a molecular weight of 53 
kilo-Daltons. The name and nomenclature of p53 protein originate from this molecular 
weight. 
A prediction of the structure of the p53 protein based on the primary sequence 
indicates three domains may be present. The first at the aminoterminus, encompassing 
amino acid residues 1 to 75, is very acidic in charge and is predicted to be in a largely 
helical conformation. The next set of residues, at amino acids 75 to 150, are quite 
hydrophobic and proline rich. The carboxyterminal domain consisting of residues 319 
to 393 in the human are very basic and could form an orderly amphipathic helix 
structure (37). 
Wild-type p53 protein has a short half-life of 20-30 minutes and is expressed 
at low level in all normal mammalian cells (66). The wild-type protein is therefore not 
gerenally detectable by immunohistochemistry (15). 
The p53 protein is a phosphoprotein. There are three major sites for 
phosphorylation. At the aminoterminus, casein kinase I phosphorylates several residues 
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(serine residue at amino acid position 7，9，12，18, 23, 37 and 58 are all candidates). 
Since this acidic domain has been demonstrated to be responsible for the action of 
RNA polymerase on a gene, phosphorylation of this acidic domain could regulate this 
process (67). The other site for phosphorylation is the amino acid residues serine-
proline at codon 316 and 317 respectively and is recognized by cdc2 like protein 
kinase (68). This phosphorylation could link p53 to cell cycle regulated kinase (67). 
A third phosporylation site is located at the carboxyterminus. Although this 
phosphorylation is appeared to be carried out by casein kinase II, the significance of 
this phosphorylation remains unknown. 
Based on early studies of wild-type p53 protein from mouse teratocarcinoma 
cells or in vitro translation of p53 mRNA in a rabbit reticulocyte lysate，the p53 
protein appears to assemble into dimers or tetramers (69,70). Later, wild-type p53 
protein was found to aggregate to form tetramers and multiples of tetramers (71). A 
C-terminal amphipathic alpha-helix region (codons 334-356) plus basic region (codons 
363-386) was reported to be responsible for this oligomerization (72). 
4.5. Wild-type p53 protein - Biochemical functions 
Studies indicated that the subcellular localization is important for the ftinctions 
of wild-type p53 protein. It only exerts its fiinctions in the cell nucleus. Hence, the 
pertinent biochemical activites of p53 are most probably associated with nuclear 
processes (56,73,74,75). 
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Using the replication of DNA viruses as a model system, wild-type p53 protein 
was suggested to play a role in the control of DNA replication. SV40 large T antigen 
is important in the initiation and propagation of SV40 DNA replication. It binds the 
origin of DNA replication on the SV40 chromosome and acts as a helicase to promote 
DNA replication; its also binds the cellular DNA polymerase required to synthesize 
SV40 DNA (76). The binding of wild-type p53 protein and SV40 large T antigen leads 
to loss of these properties of SV40 large T antigen on DNA replication (76,77,78). The 
P53 proein can inhibit the ATP-dependent helicase activity of SV40 large T antigen 
(78). These suggest that there is a cellular homologue of SV40 large T antigen and this 
homologue is responsible for the initiation of cellular DNA replication and the entry 
into the S phase. Therefore, the DNA replication is controlled by the inaction of this 
homologue with wild-type p53 protein (11). 
Recently, this cellular homologue was suggested to be Replication Protein A 
(RPA). RPA is the first cellular factor that is recruited to the initiation complex and 
its ability to bind to single-stranded DNA is essential for the first step of DNA 
replication, namely unwinding of DNA at the origin of DNA replication (79). Dutta 
A and his colleagues have observed that RPA can form a complex with p53 protein 
and this p53-bound RPA was inhibited in its ability to bind to single-stranded DNA 
(80). However, the aminoterminal and carboxyterminal regions of p53 protein were the 
sites of RPA binding, instead of the central portion where the SV40 large T antigen 
binds (80). 
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An alternative possibility is that wild-type p53 protein could act as a 
transactivator of gene transcription, either promoting or repressing messenger RNA 
synthesis. 
Cotransfection of mammalian cells with a GAL4 responsive reporter gene and 
P53/GAL4 fiision gene resulted in a dramatic induction of reporter activity when 
compared to cotransfection with the reporter gene and the GAL4 DNA binding domain 
alone (81,82,83). Deletion analysis ofp53 demonstrated that the region of p53 involved 
in transactivation is localized to the acidic domain at the aminoterminus and is 
contained within the first 42 amino acids (84). Moreover, wild-type p53 can directly 
activate the transcription of the muscle creatine kinase (MCK) gene promoter in the 
course of studying the role of wild-type p53 in muscle cell differentiation (86). 
Previously, a basic carboxyterminal region was predicted to form an amphipathic helix-
like structure and be responsible for its binding to DNA (87). However, by using 
partial proteolysis of p53, sequences within the central portion are necessary for its 
sequence-specific DNA binding properties but not the carboxyterminus (88). Precise 
mapping of the binding sequences has revealed a consensus binding site consisting of 
^ o copies of the 10 bp motif 5 '-PuPuPuC(A/T)(T/A)GPyPyPy-3 ‘ separated by 0-13 
bp (89). The nucleotide sequence sperifically recognized by wild-type p53 protein is 
TGCCT(X)5.8TGCCT, where X is any nucleotide (90)，as deduce from the MCK 
promoter which contains the sequence TGCCT-CTCTC-TGCCT (91). 
Instead of DNA binding, the carboxyterminus has been reported to contain a 
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potent DNA strand-reannealing activity (88) but the significance of this observation 
remains to be determined. 
Wild-type p53 positively regulates promoter that contain p53 specific DNA 
binding site as described before. Promoters that do not encode a p53 DNA binding site 
such as c-fos，c-jun，interleukin 6 (IL-6) and multi-drug resistance (MDR) promoter 
are generally transcriptionally suppressed by wild-type p53 in transient transfection 
assay (92,93,94,95,96,97). Cotransfection of a wild-type p53 expressing vector and a 
promoter-reporter gene into cells results in a low level of reporter activity than 
observed when cells are transfected with the reporter alone. As the number of unrelated 
promoters that a more general mechanism for suppression could be operative, p53 may 
target the core transcriptional machine. Human TATA binding protein (TBP) was 
demonstrated to play an important role in transcription. Moreover, there is an 
interaction between wild-type p53 protein and purified human TBP. It was suggested 
that wild-type p53 can suppress gene expression by inhibiting transcription through an 
interaction with the TATA binding protein (97). Somewhat unexpectedly, the region 
of p53 that interacts most avidly with TBP is the carboxyterminal portion, rather than 
the more predictable aminoterminal portion containing the activation domain (84). 
However, the idea that p53 is or regulates a transcription factor is not mutually 
exclusive of the concept that it is also involved in the initiation of DNA replication. 
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4.6. Wild-type p53 protein - Biological Functions 
In the in vitro experiments utilizing the primary rat embryo fibroblast 
transformed by cooperating oncogenes such as myc and ras or El A and ras, the 
introduction of plasmid encoding wild-type p53 protein can reduce this oncogene-
mediated transformation (51,52). Furthermore, the reintroduction of a wild-type p53 
allele using a retrovirus vector into a human osteogenic sarcoma cell line also reduced 
its tumorigenicity when studied in an animal system (26). In addition, the plating 
efficiency of a tumorigenic cell line, including a series of cell lines representing a 
variety of tumor types and species, was dramatically reduced when a wild-type p53 
gene was introduced (26,53,54,55,56,98). Therefore, wild-type p53 protein has been 
suggested to contain tumor suppression activity (26,51,52,53,54,55,56,98). 
Wild-type p53 protein can also induce a growth arrest, which occurs primarily 
in the G1 phase of the cell cycle (53,54,55,56,73,99). When a human glioblastoma cell 
line was induced to express high level of wild-type p53 protein artifically, the 
overexpression of wild-type p53 can cause a reversible growth arrest. The arrested cells 
Were found predominantly with a G1 DNA content (99). This result was supported by 
the study of Michalovitz et al (55) who showed that a temperature sensitive p53 allele-
expressed in a p53 plus ras transformed cell line behaves as a wild-type protein at 32�C 
ansd as a mutant protein at 39°C. These cells replicates at 39�C but are blocked for cell 
division at 32°C，and the block appears to be in the late G1 phase of the cell cycle. 
Hence, p53 appears to be capable of acting as a negative regulator of cell cycle 
progression (55). 
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The G1 arrest due to overexpression of wild-type p53 may represent a 
physiological function of wild-type p53. Gamma irradiation of mammalian cells 
induces double-strand DNA breaks and the irradiated cells arrest for a short period of 
time (approximately 75 hours), presumably to repair the DNA damage (100,101，102). 
Moreover, the genomic stability can be preserved by wild-type p53 protein in response 
to DNA damage (103,104). Indeed, the p53-negative murine embryonal fibroblasts did 
I 
not show growth arrest in response to the drug N-(phosphonacetyl)-L-aspartate (PALA) 
and generate drug resistance colonies at a frequency of l O � w h i c h is indicative of 
amplification of the CAD (trifunctional protein carboamoyl-P synthetase, aspartate 
transcarbanylase, dihydroorotase) gene (104). The presence of wild-type p53 gene in 
the fibroblast inhibited the gene amplification. The frequency of generation of drug 
resistance colonies decreased to less than 10"^  or 10"^ Moreover, the growth of the 
fibroblasts arrested in the presence of PALA (104). 
Experiments employing the Ml mouse myeloid leukemia cell line (clone S6) 
which contains no p53 expression have revealed that wild-type p53 expression can 
induce apoptosis (i.e. programmed cell death) in the Ml cells when wild-type p53 
allele was transfected (105). As apoptosis was employed to physiologically eliminate 
cells in which a growth deregulation has occurred, wild-type p53 protein can provide 
this protective response to growth deregulation in the cell. Based on the biochemical 
properties of wild-type p53 protein that it acts as a transcriptional regulator, wild-type 
p53 may therefore promote cell death by activating genes required for the induction 
of apoptosis (106,108,109,110,111,112,114) or by repressing genes such as bcl-2, 
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whose products suppress apoptotic processes (109,110,111,112,113,114). 
Another importance manifestation of wild-type p53 activity is the induction of 
differentiation demontrated by the introduction of stable wild-type p53 expression into 
a transformed pre-B cell line. Unlike the parental p53-negative cells, the wild-type p53 
transfectants could undergo partial differentiation in culture (115) and in in vivo system 
(75). This p53 activity was further supported by the observation that the increase in 
wild-type p53 protein level was detected during the course of normal haematopoietic 
cell maturation (116). -
4.7. Regulation of p53 function 
In a transformed mouse 3T3 cell line, the amplified gene was idenified on 
double-minute chromosome. This amplified gene was called MDM-2 gene (117). The 
amplification of MDM-2 gene can transform the normal fibroblast into a tumorigenic 
cell line (118) and the MDM-2 gene is classified to be a proto-oncogene. According 
to the amino acid sequence of MDM-2 protein, it was predicted to contain a nuclear 
localization signal, an acidic amino acid domain, and two zinc fingers which are metal-
binding sites. All of these predicted features suggested MDM-2 protein is a 
transcriptional activator (118). The product of MDM-2 gene was found to complex 
With wild-type p53 protein. Therefore, MDM-2 was assumed to express oncogenic 
properties through the inihibition of wild-type p53 functions due to the formation of 
complex (119). This result was supported by the observation that overexpression of 
MDM-2 overcomes wild-type p53 mediated suppression of transformed cell growth 
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(120). 
Recently, wild-type p53 protein has been demonstrated to be able to inhibition 
of MDM-2 gene expression through a p53 binding site located within the first intron 
of the MDM-2 gene, such that an autoregulatory model for p53 gene expression was 
postulated (121). Normally, the cells may express low steady-state levels of wild-type 
p53 and MDM-2 protein. When the wild-type p53 level was elevated, the genes 
involved in DNA repairs and G1 phase of growth arrest were stimulated to express. In 
addition, the expression of MDM-2 gene -was also increased. The elevated level of 
MDM-2 protein could inihibit wild-type p53 transactivation. This regulatory loop could 
maintain the equilibrium between the p53 tumor suppressor gene and the MDM-2 
proto-oncogene product (121). 
4.8. p53 gene mutations in human cancers 
Whereas aneuploidy is almost always found in human cancers (122), the most 
common cancer-related genetic change known at the gene level is p53 mutation (123). 
In addition to point mutations, allelic loss, rearangements, and deletions of the p53 
gene have been detected inhuman tumors (13,124,125,126,127,128). These aberrations, 
together with alterations of oncogenes and other tumor suppressor genes, make up the 
niutational network leading to malignancy. 
The first genetic evidence for p53 alterations in human tumors came from a 
study by Masuda et al (127) indicating rearrangements in the p53 gene in 3 of 6 
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osteosarcomas analysed. Also suggestive of p53 alterations were studies by Vogelstein 
and colleagues and several other groups showing allelic losses on chromosome 17p, the 
site of the p53 gene, in colon carcinomas and other types of human tumors 
(129,130,131,132,133,134,135). However, the seminal discovery of the Vogelstein 
group of point mutations (resulting in amino acid substitutions) in p53 in colon 
carcinomas accompanied by the loss of the second (presumably wild-type) allele 
resulted in a subsquent avalanche of papers describing similiar genetic phenomona in 
other human tumor types such as lung cancer (13，15), brain (134) and breast (133) 
tumors and chronic myelogenous leukemia cells in blast crisis (65). 
By the studies of p53 genes in a wide variety of human cancers, most of p53 
mutations were missense mutations. Moreover, the position of these mutations scattered 
in the p53 gene was not random. Hollstein M and her colleagues (10) examined 280 
base substitution p53 mutations in varies human cancers. All these p53 mutations were 
classified as somatic mutations because only the wild-type p53 sequences were found 
in normal cells of all cases analysed (15,136,137,138,139,140,141). 98% of these 
^nutations were clustered between exons 5 and 8 and were located in four 
evolutionarily conserved domains of p53 (domains II to V). Studies that included 
outlying exons suggested that tumor mutations outside exon 5 through 8 were rare 
(14,142,143). There are three mutational hot spots or codons affecting residues 175， 
248 and 273 (11). About 40% of total missense mutations in varies cancers were 
belonged to these hot spot mutations (67). The frequency and distribution of these hot 
spots differs among cancers from different tissue types. For example, the codon 175 
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is the hot spot mutational site for colon carcinomas (12) and Burkitt's lymphoma (144) 
but no codon 175 mutation observed in hepatocellular carcinomas which codon 249 
mutation was common (137,141). 
There are two types of mutations. One is transition in which a purine is 
substituted for a purine or a pyrimidine for a pyrimidine and the other is transversion 
in which a purine is substituted for a pyrimidine or vice versa. p53 mutations in human 
cancers are predominantly transitions at CpG dinucleotides (10,145). In colorectal 
carcinoma, transitions constitute the majority of p53 mutations and most of these occur 
at CpG dinucleotides (12,14,17,142). However, transversion occurs quite frequently in 
hepatocellular carinoma (137). 
Besides the somatic form, p53 mutations can be found in the germ line of 
families with Li-Fraumeni syndrome (146,147). Li-Fraumeni syndrome is a relatively 
rare inherited autosomal dominant condition characterized by a greatly increased 
susceptibility to a variety of tumor types. The most frequent are breast carcinomas, soft 
tissue sarcomas, brain tumors, osteosarcomas, and leukemia (148,149). Affected family 
ttiembers have a 50% probability of developing cancer by the age of 30，in contrast to 
a 1% probability in the general population. All the p53 mutations in Li-Fraumeni 
syndrome families were localized to exon 7 and between codons 242 and 258 
(146,147). However, germline mutations in exon 4 through 9 and nonsense mutations 
have been demonstrated recently (150,151,152). 
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4.9. Properties of mutant p53 protein 
One of the most consistent phenotypes of a mutant p53 protein is the 
prolongation of half-life (153,154). Instead of the normal half-life (20-30 minutes), the 
mutant p53 protein can stabilize for several hours and be present at much higher 
concentrations in cells detectable by immunostaining (15,66). According to this 
correlation between the p53 mutation and immunopositivity, many groups of 
investigators employed anti-p53 antibodies, which immunoreact with both wild-type 
and mutant p53 protein, in immunohistochemistry alone to study the accumulation of 
mutant p53 protein and indirectly the p53 gene mutation in varies human cancers 
including breast (155,156,157,158,159,160), lung (15), skin (161), colon (16,17,162) 
and ovarian (18) cancers. 
The presence of base pair substitution in the p53 gene, the gene product of this 
mutant alters its conformation and gain a new epitope in the residues 212 to 217 of 
P53 antigen. This new epitope is recognized by monoclonal anti-p53 antibody, PAb240 
(9). Since this epitope is not present in wild-type p53 protein, this PAb240 is supposed 
to recognize mutant p53 protein specifically (9) and immunohistochemistry using this 
antibody can determine the involvement of p53 gene mutation in cancers' more 
accurately. 
\ 
The formation of complex between heat shock protein (hsp) and mutant p53 
protein may be responsible for this prolongation of half-life of mutant p53 protein in 
the cell (164,165). However, this explanation cannot completely explain the fact that 
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diverse mutant proteins have increased half-life because only certain mutant p53 
proteins can form complex with this hsp. For example, the mutant p53 proteins with 
amino acid substitution at codon 143 or 175 have an ability of complex formation with 
hsp while this binding activity do not occur in the product of p53 gene with mutation 
at codon 248, 273 or 281 although all these mutants have a prolonged half-life. The 
p53-hsp complexes seen to be formed with proteins encoded by varies p53 genes 
mutated between codons 66 and 232 (166) but the essential region for the ability of 
binding of hsp is the p53 carboxyterminus (88). Moreover, this interaction between 
mutant p53 protein and hsp could inactivate the function of mutant p53 protein as the 
wild-type (167). 
In contrast to hsp, SV40 large T antigen cannot bind to the mutant p53 protein. 
The reverse condition is true for the wild-type p53 protein. The failure of binding 
between mutant p53 protein and SV40 large T antigen suggest that mutant p53 protein 
fails to inhibit DNA replication due to no binding with presumable cellular homologues 
of SV40 large T antigen which is involved in the control of cellular DNA replication 
(26). 
Moreover, mutant p53 proteins show a reduced ability to bind to DNA (87). The 
recognition of a p53 binding DNA sequence (89,90) is lost or altered upon mutation 
(168). Therefore, mutant p53 proteins cannot activate transcription from promoters 
With p53 DNA binding site. This was supported by the observation that mutant p53 
fails to promote the transcription of a test gene regulated by MCK promoter (86). 
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However, the failure in transcriptional transactivation of mutant p53 porteins is also 
due to the altered activity of transcriptional transactivation of these mutants directly 
in addition to the loss of DNA binding potential because the chimeric protein of GAL4 
DNA binding domain and a mutant p53 protein also cannot transactivate a test gene 
(169). The fact that mutant p53 proteins do not bind TBP, the ability to suppress 
promoter activity of p53 protein is lost as a result of mutation (97). Therefore, the 
biochemical properties of mutants p53 proteins are totally different from a wild-type 
P53 protein. 
When mutant p53 cDNA clones are transfected into primary rat embryo 
fibroblasts in cell culture, the cells that take up these clones and express them have a 
sevenfold enhanced platting efficiency (i.e. the ability to form colonies in cell culture 
increases sevenfold) (51). When these colonies are selected and cloned, about 50% of 
these colonies would produce immortalized cell lines that can grow forever (170). This 
is in contrast to 1 in 20 (5% efficiency) clones of cells of rat embryo fibroblast 
(without mutant p53) producing permanent cell lines in culture. Thus, a mutant p53 
gene expressed in a rat embryo fibroblast cell line enhance its plating efficiency and 
its ability to produce an immortalized cell line in culture. Each of these cell lines was 
found to contain the original cDNA clone of mutant p53 and express the altered p53 
protein in large amounts (170). The mutant p53 protein forms an oligomeric protein 
complex with the endogenous wild-type p53 protein of the rat cell (51,56). It is 
hypothesized that such mutant protein can act in a transdominant negative fashion by 
formation of hetero-oligomers between the wild-type and mutant p53 protein to 
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inactivate the growth regulatory effects of the endogenous wild-type rat p53 protein 
(51). Thus, mutant p53 proteins promote immortality of cell lines in culture (40,42,51). 
The transdominant negative fashion for the inactivation of wild-type p53 
function by mutant also is supported by the transformation studies of primary (43,44). 
It is believed that mutant p53 protein arrests wild-type p53 proteins in an inactive 
hetero-oligomers in a cooperating oncogene such as ras could lead to cellular 
transformation (50). 
Alternatively, mutant p53 protein may express an oncogenic activity as a gain 
of function phenotype, which is required for immortalization and/or transformation. 
When mutant p53 alleles are introduced into non-tumorigenie cell lines such as the L12 
Abelson murine leukemia virus-transformed cell line (171) and murine fibroblast (10)3 
cell line (121) which are devoid of endogenous p53, this introduction can transform 
the cells to acquire the tumorigenic potential. This eliminates the notion that this 
mutant p53 protein confers acquired tumorigenicity upon a cell by complexing with 
an endogenous wild-type p53 protein and inactivates its function. Rather, this 
observation demonstrates that some mutant p53 alleles produce a faulty protein with 
a gain of function mutation (75). 
H. 5. Human Papillomavirus (HPV) 
义 1. Virion Structure 
Papillomaviruses are small, nonenveloped, icosahedral DNA viruses that 
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replicate in the nucleus of squamous epithelial cells. The virion particles consist of a 
single molecule of double -strand circular DNA approximately 8,000 base pairs in size, 
contained within a spherical protein coat, or capsid, composed of 72 capsomeres (172). 
The papillomavirus particles are 52-55 nm in diameter. The capsid consists of at least 
two structural proteins. The major capsid protein has a molecular weight of 
spproximately 50,000 daltons (173,174,175) and represents approximately 80% of the 
total viral protein. A minor protein has a molecular weight of approximately 70,000 
daltons. Both of these proteins are encoded by two of the open-reading frames (LI and 
L2) of the viral genome. In addition, analysis of protein in the vitrus particle reveals 
that the DNA of the viral genomes is associated with cellular histones to form a 
chromatin-like complex (173,175). 
5.2. Classification 
Historically, the papillomavirus were grouped together with the polyomavirus 
to form the papovavirus family. The term papovavirus is derived from the first two 
letters of the virus first grouped together to form this family of viruses: rabbit 
papillomavirus, mouse /polyomavirus, and simian vacuolating virus. The properties 
shared by these viruses include small size, a nonenveloped virion, an icosahedral 
eapsid, a double-stranded circular DNA genome, and the nucleus as a site of 
inultiplication. 
The papillomavirus DNA are classifiied according to their sequence homology. 
More than 65 different human papillomavirus types have been recognized. In order for 
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a papillomavirus isolated to be considered a new type, it must share less than 50% 
homology with the other known types when the hybridization analysis is carried out 
under stringent conditons in liquid phase (176). 
5.3. Papillomaviruses in Human Cancers. 
Papillomaviruses are associated with naturally occurring cancers in human. The 
first convincing link of specific huamn papillomaviruses with human cancers was 
shown between HPV-5 and HPV-8 and the cutaneous carcinomas in patients with a 
rare lifelong disease called epidermodysplasia verruciformis (177). These patients are 
unable to resolve their wart virus infection and some of the warty lesions may progress 
to malignancy (178,179). 
There are over 60 different HPVs associated with a variety of clinical lesions 
(180), and approximately 20 of these are assoicated with anogenital tract lesions. Some 
of these; such as HPV-6 and HPV-11, are considered low risk viruses since they are 
assoicated with benign proliferative lesions such as condyloma accuminata that 
infrequently progress to malignancy. Others, including HPV-16 and HPV-18, are 
considered high risk because of their assoication with potentially preneoplastic lesions 
and with certain anogenital carcinomas, most notably cancer of the uterine cervix 
(181). 
The HPV E6 and E7 genes are regularly expressed in HPV positive cervical 
cancers and derived cell lines (182,183,184). Genetic analyses have shown that the E6 
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and E7 genes are both necessary and sufficient for the efficient immortalization of 
primary human squamous epithelial cells (185,186). Similar to other DNA virus 
oncoproteins, the E6 and E7 proteins interact with tumor suppressor gene products. 
SV40 large T antigen, adenovirus ElA and the HPV E7 proteins can each associate 
with pRb, retinblastoma gene product (187,188), and the E6 proteins of HPV-16 and 
HPV-18, like SV40 large T antigen and adenovirus 5 ElB protein, associate with p53 
(34,35,189,190). The E7 proteins of the high risk HPVs bind to pRb with a higher 
affinity than E7 proteins of the low risk HPVs (191). The stable association of E6 with 
p53 in vitro has been observed only with the high risk HPV proteins and in vitro 
experiments have shown that the high risk HPV E6 proteins stimulate the degradation 
of p53 via the ubiquitin-dependent proteolysis system (192). This suggests that these 
interactions may be important determinants of the oncogenic potential of the different 
HPV typ es. Further evidence for the relevance of the E7-pRb and E6-p53 interactions 
in which the Rb and p53 genes have been examined in HPV DNA were found to 
express wild-type pRb and p53, while lines lacking HPV DNA contained mutations at 
both the Rb and p53 genes. This suggests that inactivation of pRb and p53 is important 
in cervical carinognenesis, and that inactivation can occur either through the action of 
the E6 and E7 proteins in the HPV positive cancers, or through mutation in the HPV 
恥gative cancers. 
^•^.Relationship Between p53 alteration and HPV infection 
Wemess et al. (193) demonstrated that the E6 proteins of HPV 16 and HPV 18 
form complexes with human and murine p53 protein in in vitro binding assays. 
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Subsequent studies have indicated that even E6 protein from "low risk" virus, such as 
HPV 6 and HPV 11 which are only associated with benign warts, may bind p53 but 
at a lower avidity (194). It is clear that "high risk" HPV 16 and HPV 18 E6 protein 
actively stimuate degradation of bound p53 through ubiquitin-dependent proteolysis, 
while "low risk" E6 proteins were unable to show any degradation effect (194). These 
results suggest that the E6 protein of oncogenic papillomavirus abrogates p53 function 
by faciliating its degradation. 
p53 protein levels are greatly reduced also in HPV-positive cervical cancer 
derived cell lines and cell lines experimentally immortalized by HPV E6 and E7 or by 
E6 alone, providing further in vitro evidence for the rapid degradation of p53 in E6 
containing cells (195). The HPV-positive cervical cancers usually contained wild-type 
P53 (196). In contrast, HPV-negative cervical cancinomas were often found to contain 
high levels of mutant p53 protein (196) indicating that two routes of p53 inactivation 
are possible in cervical cancer:(i) in HPV-positive cases, the p53 remains wild-type but 
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IS rapidly degraded; or (ii) in HPV-negative cases, the p53 gene is mutated and then 
protein is functionally altered. Because of these known relationship between HPV and 
P53, we included a study of HPV infection in the prostatic lesions. ‘ 
fi- 6. p53 alterations and Prostate cancers 
Cytogenetic studies 
The critical distinction to be made for tumor suppressor genes is loss of function 
associated with the emergence of cancerous behavior of cells. The earliest indications 
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of such loss of function were cytogenetic studies documenting non-randon chromosome 
alterations, including deletion, unbalanced translocation, and monsomy, seen in 
metaphase spreads of various human cancers (197). For example, cytogenetic studies 
showed that interstitial deletion of chromosome 13q frequenctly occurred in tumor or 
somatic cells of patients with retinoblastoma and this provided the earliest clue for the 
presence of tumor suppressor gene, Rb. 
Clonal structural or numerical aberrations examined by cytogenetic study have 
been i d e n t i f i e d in 49 of 185 p r i m a r y p r o s t a t e c a n c e r s 
(198,199,200,201,202,203,204,205), but the most consistent cytogenetic finding has 
been a normal male diploid karyotype (199,200,202,203,204,205). However, the 
predominant of diploid cells in the majority of tumors studied could be due to selection 
in vitro. As in most epithelial neoplasms, prostate cancers showed no consistent 
cytogenetic alterations. The most common clonal change is loss of the Y chromosome 
and trisomy 7 but the significance of these changes are in doubt because both have 
been observed in normal tissues (206,207,208,209,210,211). Chromosomes repeatedly 
affected by structural alterations include 1, 2p, 7q, 8p, and lOq and break points cluster 
in so-called hotspots in 2pl3-p23, 7q22-31, and 10q22-24 (198,202,204,212).-
6二 Hybridization analysis 
Microscopic genetic loss, which is undetectable by cytogenetic studies, may be 
assessed by molecular analysis of DNA sequence polymorphisms that distinguish 
between the two homologous copies of autosomal loci. Twenty-eight prostate cancer 
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specimens have been examined by Carter BS and colleagues (213) for loss of 
heterozygosity at 11 different chromosomal arms including 3p, 7q, 9q, lOp，lOq, l ip , 
13q, 16p, 16q, 17p and 18q. Allelic losses of lOq and 16q were the most common 
(approximately 30% each), following by less frequent loses of 13q (23%); 17p and 18q 
(17%)； and 3p, 7q and 9q (10-15%). Since p53 gene is located at the short arm of 
chromosome 17, 17p, allelic loss at this region in about one-fifth of prostate cancers 
suggested a potential role for inactivation of the p53 gene in human prostatic 
tumorigenesis (213). 
6.3. p53 alterations in prostate cancer cell lines 
Isaacs WB and his colleagues reported on the mutational status of the p53 gene 
in prostate cancer cells and provided functional evidence that the wild-type p53 gene 
J^ay have a role in suppressing prostatic tumorigenesis by studying 5 human prostate 
cancer cell lines derived from one primary prostate cancer (PC-82) and four metastatic 
prostate cancers (TSU-Prl, LNCaP, PC-3 andDU145). Sequence analysis of exons 5-8 
of the p53 gene revealed that three of five prostate cancer cell lines (TSU-Pr-1, PCS 
and DU145) contains mutations which alter the amino acid sequence of this most 
highly conserved portion of the gene. Transfection of the wild-type gene versus a 
Mutated p53 gene into two cell lines with p53 mutations resulted in reduced colony 
formation. Wild-type p53 gene expression is apparently incompatible with continued 
欧owth of these tumor cells inasmuch as none of the colonies which formed after wild-
type transfections retain the transfected p53 sequences. Immunocytochemical data 
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indicated that prostate carcinoma cells expressing the transfected wild-type p53 gene 
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are growth arrested because they exhibit a reduced level of thymidine incorporation 
into DNA (214). 
However, this p53 alterations could be acquired during the cloning and the 
properties of prostate cancer cells in cell lines probably show some deviations from the 
cancer cells in primary prostate cancer specimen. Moreover, all cell lines showed p53 
alterations were derived from the metastatic prostate cancers but the PC-82 cells from 
a primary prostate cancer did not exhibit any p53 alteration in this study (214). 
Therefore, a study of p53 alterations in primary prostate cancer specimens is necessary 
for determining the role of p53 gene in the prostate tumorigenesis. 
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III. OBJECTIVES OF STUDY 
1 • To investigate p53 protein accumulation in prostatic carcinomas and hyperplasias 
using p53 immunohistochemistry. 
To determine whether allelic loss of the loci on the chromosome 17 is involved 
in the genesis of prostatic carcinomas and hyperplasias as determined by 
hybridization analysis. 
To evaluate the incidence of p53 gene mutation in prostatic carcinomas and 
hyperplasias by PCR-SSCP analysis on the exons 4-8. 
To determine any relationship among p53 protein accumulation, allelic loss of 
the loci on the chromosome 17 in prostatic carcinomas and hyperplasias 
To detect any HPV infection in prostatic carcinomas and hyperplasias by PGR 
method, as p53 functional inactivation can be induced by HPV, due to p53 
degradation by forming complexes with HPV E6 protein 
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IV.MATERIALS & METHODS 
IV.l. Patients & Materials 
A total of 48 men were studied. Of these, 30 (mean age 72+8 years) underwent 
transurethral prostatectomy (TURP) in the Department of Surgery, Prince of Wales 
Hospital in 1992 for bladder outflow obstruction and clinically benign prostate glands; 
On subsequent histological examination, all of them were diagnosed as benign prostate 
hyperplasias (BPH). The remaining 18 men (mean age 73+9 years) with clinical 
presentation and impression of cancer in the majority of cases underwent TURP for 
diagnosis and/or relief of outflow obstruction. All 18 cases were diagnosed as 
adenocarcinoma of prostate (no other types of prostatic cancers were encountered 
during the period of study). 
Histological Grading 
Prostatic adenocarcinoma was grade according to the scheme proposed by 
Gleason and by Mostofi (19,20,24) as followed: 
2 l Sieason Grading 
^ Single, separated, uniform small glands in closely packed circumscribed masses 
2 • 
Single, separated, less uniform glands, loosely packed less circumscribed edge 
Irregular glands, infiltrative, cribiform pattern, papillary pattern 
4 Ragged infiltrative sheets of tumour or fused glands, with or without clear cells 
Ragged infiltrative sheets of tumour with minimal glands identified 
S J L O . Grading (Mostofi^ 
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1 Well-differentiated tumour，small glands, slight nuclear anaplasia 
2 Moderately differentiated, cribiform or fused glands, moderate nuclear anaplasia 
^ Poorly differentiated tumour, little or abortive glands, marked nuclear anaplasia 
IV.3. Staging of Prostatic Carcinoma 
Stage A Clinically unsuspected cancer, 
diagnosis made in specimens removed for presumed hyperplasia. 
Stage B Palpable tumour which remains localized or confined to the prostate. 
Stage C Tumour that has extended out of the prostate gland. 
Stage D Tumour with recognized distant metastasis. 
The staging system used in our patients is the TNM classification proposed by 
the Union Internationale Contre le Cancer (UICC) and is as follows: 
Tumour is an incidental histologic finding: 
Tla - tumour with 3 or less foci 
Tib - tumour with more than 3 foci. 
Tumour is clinically or grossly limited to the gland 
T2a - tumour measuring 1.5 cm or less ‘ 
T2b - tumour measuring more than 1.5 cm or involving 2 lobes. 
Tumour invades beyong the prostatic capsule, the bladder neck 
or seminal vesicles, not fixed. 
Tumour is fixed and invades other adjacent structures of the pelvis. 
Metastasis in a single regional lymph node, 2 cm or less. 
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N2 Metastasis in a single regional or multiple lymph nodes, 2-5 cm. 
N3 Metastasis to lymph node, more than 5 cm. 
Ml Distant metastasis. 
TX, NX, MX item cannot be assessed. 
To, NO, MO no tumour or metastasis is found in specimen. 
IV.4. Collection of tissues and blood samples -
Paired samples, including both prostatic tissues and blood from each patient 
Were received from the operation threatre. 10 ml of fresh blood was collected in the 
15 ml Falcon conical tube containing 2 ml of acid citrate dextrose solution (ACD)i as 
source of patient's normal DNA. Fresh prostatic tissues consist of fragments varying 
between 0.5 to 2.5 cm in largest diameter. For each patient, selected fragments were 
immediately bissected such that one half was frozen in liquid nitrogen (-196�C) and 
then stored at -70�C and the other half was fixed in formalin and processed as routine 
for histological diagnosis. Each bissected fragment was carefully labelled such that 
frozen tissues and histological sections were matched. When sufficient amount of 
tissues permitted, 27 fragments were bissected and the remaining fragments were all 
embedded by filling as many casettes as it was necessary. In doing so, the histological 
sections of the half fragments guided the selection of the counterpart frozen fragment 
for DNA extraction. The percentages of prostatic epithelial cells in BPH and in prostate 
carcinoma were estimated by examination of haematoxylin and eosin (H&E) stained 
tissue sections. Only the fragments with 70% or more of epithelial elements were 
chosen for DNA extraction, subsequently for p53 gene analysis and detection of human 
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papillomavirus by Polymerase Chain Reaction method. Fragments with urethral 
epithelium were excluded from the study. For immunohistochemistry, frozen prostatic 
fragments were mounted in OCT compound before sectioning. 
IV.5 Immunohistochemical studies of prostatic hyperplasia and carcinomas 
5.1. Antibodies used 
D07 (Dakopatts) recognizes both the wild-type and mutant p53 protein. -This 
antibody raised against the recombinant human wild-type (non-mutant) p53 protein 
expressed in Escherichia coli and is used in formalin-fixed tissue sections (215). 
Monoclonal antibody PAb240 (Oncogene Sciences) was generated against fragments 
of murine p53 protein amino acids 14-389, expressed in bacteria; it recognizes a 
denaturation-resistant epitope located between aminoacids 156 and 335, detecting the 
Mutant-type p53 protein as determined by an immunoprecipitation assay and is used 
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in frozen tissue section only (216). 
Methods in frozen sections 
6 microns thick frozen sections of prostatic fragments were obtained on the 
eryostat machine (American Optical), thaw-mounted on gelatin (BDH)-coated glass 
slides and air-dried. All subsequent steps were performed at room temperature. The 
Sections were then fixed for 10 minutes in 100% acetone (Merck) and were immersed 
in 0.3% hydrogen peroxide (Merck) in absolute methanol (Merck) to quench 
endogenous peroxidase activity. Removing the methanolic hydrogen peroxide solution 
by Washing the sections three times with TBS^ was followed because any methanol can 
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inhibit the reaction of antibody with antigen. Tissue were then treated in 5% normal 
rabbit serum (Dako) in TBS for 20 minutes at room temperature in order to block the 
non-specific binding before being incubated overnight at room temperature with the 
primary monoclonal antibody, D07 diluted 1:50 in TBS and PAb240 diluted 1:10 in 
TBS. After washing three times in TBS in 10 minutes, tissues were covered by 
secondary biotinylated mouse anti-rabbit antibody (Dako) with a dilution of 1:200 and 
the avidin-biotin complex (l:100)\Dako). Careful rinses were done with 3 changes of 
TBS in 10 minutes between each stages of the procedure. The color was developed 
With DAB solution4. Methyl green solution was applied for 10 minutes as counterstain. 
5.3. Methods on paraffin sections with microwave antigen retrieval method (217， 
218,219) 
Microwave antigen retrieval technique as initially described by Shi et al (217) 
Was modified by method reported by Leong and Gown (218,219). 4 microns thick 
paraffin sections were collected on slides coated with poly-L-lysine solution^ (Sigma). 
The specimens were then dewaxed in xylene (Mallinckrodt) and rehydrated in graded 
alcohol and finally in distilled water. The deparaffinized tissue sections immersed in 
a 10 mM citrate buffer pH 6.0^ were heated in a mircowave oven with middle-high 
power. After boiling for 5 minutes, the hot citrate buffer was changed by cool one. The 
Sections were reheated as above until boiling for 5 minutes. The specimens were left 
at room temperature in the hot buffer for 30 minutes to cool down the temperature 
back to room temperature. Washing the tissue sections by distilled water was done to 
remove the citrate buffer. Then, the endogenous peroxidase were quenching by 
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incubation of sections in 0.6% hydrogen peroxides in TBS for 20 minutes at room 
temperature instead of methanolic hydrogen peroxide for frozen sections. The blocking 
serum, primary antibodies, secondary antibodies, tertiary antibodies and DAB solution 
Were applied as described for frozen sections. Finally, the sections were counterstained 
lightly by Harris' Haematoxylin solution^ 
5.4. Controls 
The specificity of immunohistochemical reactions was controlled by omitted the 
primary anti-p53 antibody and by replacing this primary antibody by normal rabbit 
serum. Tissue sections of breast carcinomas served as positive controls for both 
antibodies since breast carcinoma has been shown to express mutant p53 proteins 
(159,220). 
Immunohistochemical evaluation 
Nuclear staining by the anti-p53 antibody appeared as a brown precipitate and 
Was considered as a positive result. Cytoplasmic staining alone was considered a 
negative result. A immunohistochemistry is interpreted as positive when 10% more of 
tumor cells were stained with the antibody. Weak nuclear immunostaining, in the 
absence of background staining when recognised is interpreted as positive. 
1V.6 Extraction of DNA from Blood and Tissue samples 
Extraction of genomic DNA from Blood samples 
High molecular weight genomic DNA was extracted by phenol/choroform 
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method (221). For DNA extraction from fresh blood in acid citrate dextrose solution, 
the blood sample was centrifUged at 3500 rpm for 10 minutes and then the supernatant 
plasma was discarded. Using a pasteur pipette, the buffy coat was carefully transferred 
to a fresh 15 ml Falcon conical tube and then 9 ml of autoclaved distilled water was 
added to hydrolyse the red blood cells. Further hydrolysis of white blood cells was 
prevented by addition of 1 ml lOX PBSl The white blood cells were pelleted by 
centrifugation at 2000 rpm for 10 minutes. Repeating these steps twice, the pelleted 
cells were digested overnight at 55�C in 5 ml of digestion buffer^®. Following overnight 
incubation, the solution was cooled and the cellular DNA was extracted by mixing 
gently with 10 ml ice-cold 25:24:1 (v/v/v) phenol/choroform/isoamyl alcohol solution" 
for 10 minutes. The mixture was then frozen at -20�C for 10 minutes and spun at 4000 
印ni for 20 minutes. The upper aqueous phase was collected by mixing with one-tenth 
Volume of 3M sodium acetate and two volumes of freezed absolute ethanol 
(Merck). The DNA precipiate was pelleted at 4000 rpm for 20 minutes, washed once 
With freezed 70% ethanoP，and finally dissolved in 5 ml of TE Any RNA 
present was digested by lOOug/ml DNase-free RNase A^^  for 2 hours at 37°C. The 
enzyme was in turn broken down by 0.5% SDS (BRL) together with proteinase K^^  at 
lOOug/ml for 1 hour at 55�C. The DNA was again extracted with 
phenol/choroform/isoamyl alcohol solution, precipitated with ethanol, and dissolved in 
TE PH7.5. The yield of DNA was finally determined spectrophotometrically. 
The yield and purity of the DNA obtained was determined by measuring the 
absorbance of the diluted DNA sample at 260 nm, 280nm and 330nm using the Gilford 
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Response UV-VIS spectrophotometer (a Coming Laboratory Science Co.) (221). 
Purity Check: The ratio of (八260-八330)/(八280-八330) = 1.8 to 2.0 
The ratio below this range indicates remaining small amount of protein in the sample. 
Above this range represents the presence of RNA remained. 
DNA concentration (ug/ml): DNA conc. = (A細-A330) X DF X 50 
Where Aj^ q, Ajgo and A330 are absorbance at respectively 260 nm, 280 nm and 330 nm; 
and DF is the dilution factor. One unit absorbance at 260 nm equals 50 ug/ml DNA. 
Extraction of genomic DNA from Tissue samples 
The prostatic chips with high percentage of prostatic epithelial cells for BPH 
and cancer cells for prostate cancer were chosen for DNA extraction. To prepare DNA 
仕om them, frozen tissues were allowed to thaw and then minced into tiny pieces with 
scissors. Proteinase K-SDS digestion was carried out in a 50 ml Falcon conical tube 
(Becton Dickson，Labware) and the genomic DNA was extracted and quantitated in 
exactly the same way as described for blood samples. The DNA samples obtained were 
stored at -20�C for future use. 
IV.7 Hybridization analysis 
7 Preparation of Cloned DNA Probes 
The four DNA probes, pYNZ22, php53B, pTHH59 and pUCEJ6.6, employed 
in this study were provided by American Type Culture Collection (ATCC). Three of 
them, pYNZ22, php53B and PTHH59, were inserted into plasmid vector pBR322. The 
instead of pBR322 was a vector for the pUCEJ6.6. All of the plasmids were 
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transformed into E.coli HBIOI. The relevant information of these four probes was 
listed in Table 5 (next page). 
7.2. Transformation of CaClj-treated competent cells 
The CaCl2-treated competent cells (50 ul per Eppendorf tube) prepared by Mr. 
Yiu K.C. were allowed to thraw at 4°C. Before completely defrosted, they were put on 
ice and left there for 5 minutes. Ten nanograms of recombinant plasmid DNA in TE 
PH8.017, less than lul in volume, was added and the mixture was incubated in ice bath 
for 20 minutes. The cells were then heat-shocked in 37�C water bath for 90 seconds 
and freeze-shocked in ice-water bath for 5 minutes. Afterwards, 500ul pre-warmed LB 
brothi8 was added to each Eppendorf tube and the transformation mixture was 
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incubated without agitation at 37°C for 1 hour. 50 ul of this mixture was finally spread 
onto LB agar plates'^ containing 25 ug/ml ampicillin^® which were then incubated at 
37�C overnight. 
Cultures of Transformants 
Isolated colonies of the transformants appeared on the agar plates were picked 
With a flame-sterilized inoculating loop and streaked directly on the ampicillin LB agar 
plate to check for the presence of ampicillin-resistance marker. After overnight 
incubation at 37�C, single isolated colony was picked and inoculated into 5 ml of LB 
broth medium in 15 ml Falcon conical tube. A fresh batch culture was obtained 
thereafter by overnight incubation at 37�C with good aeration. In a 250 ml conical 
Oask，0.5 ml of an overnight culture was inoculated into 100 ml of fresh LB broth 
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T^ble 5: Characteristics of DNA probes used for hybridization analysis 
pYNZ22 php53B pTHH59 pUCEJ6.6 
^ C C No. 57574 57254 57556 41028 
J ^ p Position 17pl3.3 17pl3.1 17q23-25.3 llpl5.5 
J^oc^ D17S5 TP53 D17S4 HRAS 
J^gment Size 1.7kb 2kb 3.8kb 6.6kb 
.Vecto pBR322 pBR322 pBR322 pBR322 
, ^ n i n g site BamH I BamH I Pst I BamH I 
[Hggt Organism E.coli HBlOl E.coli HBlOl E.coli HBlOl Kcoli HBlOl 
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medium containing 50 ug/ml ampicillin. The culture was incubated at 37�C with 
shaking for 6 hours. In order to improve the yield of plasmid DNA, chloramphenicol^^ 
Was added to 200 ug/ml, and the culture was again incubated overnight with shaking 
at 37°C. 
7.4. Isolation of plasmid DNA from transformant cultures 
The cells of choramphenicol-amplified culture were harvested by centrifugation 
at 4000 rpm for 20 minutes. The cell pellet was resuspended in 4 ml of buffer P P and 
left at room temperature for 10 minutes. The cells were then lysed by mixing the cell 
suspension thoroughly with 8 ml of freshly made ice-cold buffer by gently 
inverting the tube several times. After standing on ice for 5 minutes, 4 ml of ice-cold 
buffer P324 was added and the mixture was incubated in ice bath for 30 minutes to 
precipitate the high molecular weight bacterial chromosomal DNA and cell debris. The 
precipitate 
was removed by centrifugation at 16000 rpm for 45minutes at 4°C. The 
supernatant with the plasmid DNA was then collected for purification of plasmid by 
&agen>plasmid< kit (Diagen GmbH)^^ In brief, the Qiagen column containing a 
^nion-exchange reesin for adsorption of plasmid DNA was equilibrated by applying 3 
ml of QB b u f f e r ^ 6 into column. After all the solution came out, the supernatant with 
plasmid DNA was added into the column and re-loaded two more times. The plasmid 
^ ^ A was bound onto the surface of this resin column. The column then was washed 
对th 5 ml of QC buffer^7 胁ice. 5 ml of QE buffei^^ with high concentration was used 
to elute the plasmid DNA out of the column. The plasmid DNA in the elution was 
precipitated with 0.7 volume of isopropanol and kept at -20°C overnight. The plasmid 
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DNA precipitate was pelleted by centrifugation at 4000rpm for 30 minutes at room 
temperature. The DNA pellet was washed with cold 70% ethanol and then dissolved 
in 100 ul of TE pH8.0. The yield of the plasmid DNA was determined 
spectrophotometrically and the DNA was stored at -20°C. 
7.5. Purification of DNA Probe by Electroelution (222) 
The DNA probe released from the cloning vector such as PBR322 and pUC13 
by digestion with restriction endonucleases (BRL), BamH I for pYNZ22, php53B and 
PUCEJ6.6 and Pst I for pTHH59, under the conditions recomended by the 
'Manufacturer. Typically, in a reaction volume of 20 ul, 1 ug of DNA was mixed with 
2 ul of lOX reaction buffer supplied by the manufacturer and 2 units of restriction 
enzyme in an Eppendorf tube. After making up the reaction volume with autoclaved 
double distilled water, the reaction mixture was incubated at 37°C overnight. 
Before electrophoresis, the reaction mixture was heated in 68°C water bath for 
minutes to denature the DNA digests and then quickly chilled on ice to keep their 
deiiaturation status of DNA digests. The denatured DNA digests mixed with loading 
buffer consisting of glycerol, xylene cyanol FF and bromophenol blue were loaded into 
the Wells of 0.8% agarose geP^ containing 0.1 ug/ml ethidium bromide^® and then 
electrophoresis at 20 voltages (Model 250, BRL) for 18 hours was performed in 1 X 
as electrophoresis buffer in a horizontal gel electrophoresis system (Model H3, 
The size marker�！ ^jg^ ran through the agarose gel with DNA samples. The 
electrophoretic pattern was visualized by UV illumination (Transilluminator TS-36, 
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Ultra-violet Products, Inc.) and recorded by Polaroid DS34 direct screen instant camera 
using Polaroid 667 film (ASA 3000). The slice containing the band of interest was cut 
out with a sharp scalpel (Paragon Razor Co.) and placed into a prepared dialysis tubing 
filled with 0.5X TBE. The dialysis bag was then immersed in a shallow layer of 0.5 
X TBE in an electrophoresis tank. The DNA probes were electroeluted out of the gel 
onto the inner wall of the tubing by passing current through the bag for 2 hours at 100 
Voltages. In order to push the DNA back into the electrophoresis buffer, the—polarity 
of the current was reversed for about 3 minutes and all the buffer in the dialysis bag 
Was then collected by a Pasteur pipette. The DNA probes were concentrated by 
^^ntricon-30™{Am\Qor^ according to the conditions recommended by the 
Manufacturer. After the identity of the DNA probe was confirmed by gel 
electrophoresis through 0.8 % agarose minigel (Model H6 "Baby Gel", BRL), it was 
stored at -20°C. 
Radioactive Labelling of DNA Probes 
The DNA probes were radioactively labelled with [a-^^P]dCTP 
(Amersham)(3 OOOCi/mmol) by employing a Megaprime DNA labelling system" 
(^mershain). 
In the DNA labelling reaction, 25 ng of DNA probe was mixed with 5 ul of 
Primer solution34 and the appropriate amount of water was added to give a total 
Volume of 50 ul in the final Megaprime reaction. Heating the mixture to 95-100°C for 
minutes in a boiling water bath was used to denature the double stranded DNA 
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probes in the presence of nonamer primers. The annealing the DNA probes with 
nonamer primers was allowed at room temperature for 5 minutes. The primer-template 
complex was a substrate for the "Klenow" fragment of DNA polymerase I, to 
incorporate labelled nucleotides in the presence of unlabelled deoxynucleotides such 
as dATP，dGTP and dTTP, TBE pH7.5, magnesium chloride and 2-mercaptoethanoL 
Therefore, 5 ul of [a -^^P]dCTP, lOul of Megaprime reaction buffer^^ and 2 ul of 
enzyme solution^^ were added and then the mixture was incubated at 37�C for 30 
minutes. After this period, the reaction was stopped by the addition of 2 ul of 0.5M 
EDTA pHS.O^l Before purification, 50ul of STE solution was used to make the final 
Volume of solution to be lOOul. 
7.7. Purification of Radioactive Labelled DNA Probes by Spun-column 
In order to minimize the degree of non-specific binding during hybridization, 
the unincorporated [a-^^P]dCTP was removed together with the unlabelled 
deoxynucleotides in Megaprime buffer solution. 
For preparation of Spun-cloumn, a 1.0 ml syringe (Japan Medical Supply Co., 
L t d ) was plugged with a small piece of siliconized glass wool and then placed in a 
ml Falcon conical tube, in which a decapped 1.5 ml Eppendorf tube had been 
inserted. Equilibrated Sephadex G50 (Pharmacia AB Mlocecular Biology) in STE^^ 
纽led the syringe and then was packed down by centrifligation at 3500 rpm for 4 
Minutes. Re-filling with Sephadex and centriftigation were repeated until the column 
Was packed to a volume of 1 ml and then the column was washed with 0.1 ml of STE 
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3 times. After washing, lOOul of radioactive labelled DNA probes from above was 
applied into the column and 100 ul of the effluent as purified radioactive labelled DNA 
probes was collected in a fresh decapped 1.5 ml Eppendorf tube by centrifligation at 
3500 rpm for 4minutes as above. 
7.8. Southern Blotting Technique 
The Southern blotting technique was developed by Southern E.M. in 1975 (223) 
to transfer the size-fractionated DNA fragments from a gel matrix to a solid support. 
20 ng of genomic DNA samples were cleaved with the appropriate restriction 
endonuclease (BRL), Hinf l for pYNZ22, Bgl II for php53B, Taq I for pTHH59 and 
BamH I for pUCEJ6.6. Before electrophoresis, the reaction mixture was heated in 
68oC water bath for 10 minutes to denature the DNA digests and then quickly chilled 
on ice to keep their denaturation status. The denatured DNA digests was 
electrophoresed in the 0.8 % agarose gel without ethidium bromide at 20 voltages fro 
12-16 hours.. The DNA fragments in the agarose gel was stained with 0.6 ug/ml 
ethidium bromide in IX TBE for 30 minutes at room temperature with shaking after 
electrophoresis. Under the UV illumination, the electrophoretic pattern was recorded 
and the sites of the size marker's bands were marked by puncturing the gel. Before 
transferring the DNA to Nylon membrane (Hybond-N+ membrane, Amersham), the 
^ ^ A in the agarose gel was denatured by soaking the gel in the denaturation solution^^ 
for 45 minutes. It was used to denature the DNA for subsequent hybridization. The 
agarose gel was neutralized for 45minutes by neutralization solution'*® and then it was 
already suitable for blotting. 
6 1 
The plastic tray was filled with 20 X SSC^' as blotting buffer and a plateform 
Was made and covered by a Whatman 3MM wick (Whatman Laboratry Products) 
soaked with 20 X SSC. The inverted agarose gel, with the original underside became 
upperside, was transferred upward from the gel onto the membrane through the 
absorption of buffer by a stack of blotting pads (BRL) placed on the membrane with 
a 3 sheets of Whatman 3MM paper wet with 20 X SSC in between and a weight of 
0.5-1 kg on the top. Trapping bubbles between each layers was avoided. The transfer 
Was allowed to proceed overnight. After blotting, the apparatus was carefully 
dismanlted. Before removing the membrance, it was marked the bandes of DNA size 
marker with pencil to allow identification of the size marker in autoradiograph. 
The DNA fragments adsorbed on the membrane was fixed by alkaline solution. 
Therefore, the membrane with DNA fragments was enclosed by Whatman No. l filter 
Paper saturated with 0.4 M sodium hydroxide (NaOH) for 30 minutes. After rinsing 
briefly by immersion in 5 X SSC for 1 minute, the membrane was baked at 60°C for 
2 hours and stored in desiccator for future hybridization. 
Hybridization of DNA blots with radioactive labelled DNA Probe 
The principle of hybridization is that a single-stranded DNA probe can base-pair 
to a second DNA molecules that contains a complementary sequence, with the stability 
of the hybrid depending on the extent of base pairing that occurs. 
A hybridization procedure can be divided into three stages. First, the membrane 
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Was incubated overnight in a pre-hybridization solution'^ ^ in a heat-sealable 
polyethylene bag (Dazey Corporation) at 42°C with shaking to block nonspecific DNA 
binding sites on its surface, thereby reducing background hybridization. In the second 
stage, the pre-hybridization solution was replaced by hybridization solution'^ ^ and a 2 
days incubation was carried out at 42°C to allow the probe to bind to target sequences 
in the immobilized DNA. In the final stage, the membrane was washed with a series 
of conditions listed in table 6 (next page) that gradually removed bound probe 
molecules until only highly matched hybrids remained. After washings, the membrane 
Was wrapped by Saran-Wrap^^ Brand Plastic Film (The DOW Chemical Co.) and 
exposed to X-ray film {Hyperfilm™, Amersham) in light-tight cassettes with two 
intensifying screens at -70�C for 1-6 days (224). 
IV.8 Polymerase Chain Reaction - Single Stranded Conformational 
Polymorphism (PCR-SSCP) analysis 
In PCR-SSCP analysis (225)，the target sequence in genomic DNA was 
simultaneously amplified and labelled by using radioactive labelled primers. The 
amplified product was then denaturated to a single-stranded form and subjected to 
nondenaturing polyacrylamide gel electrophoresis. Bands of the single-stranded DNA 
at different positions in the autoradiogram indicate the presence of mutations. 
5，-end radioactive labelling of primer 
In the present study, 5'-end labelling kit'^ '^  (Amersham) was employed to 
radioactively label the primers (listed in Table 7，page 65) with [y-^^PJATP 
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Table 6: Stringency washing conditions 
__ Step Washing solution Temperature Duration No. of times 
_ 1 2XSSC ^ 10 minutes 2 
2 2XSSC R.T. 10 minutes 2 
/0.1%SDS 
3 2XSSC 55°C 30 minutes 1 
/0.1%SDS 
4 IXSSC 55°C 30 minutes 1 
/0.1%SDS 
L 5 IXSSC ^ 10 minutes 1 — 
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Table 7 ： p53 exons 4-8 primer sequences for PCR-SSCP analysis 
B Primer 
明加 names* PCR-amplified region Nucleotide Sequence PGR product size ref 
紐on 4 4L codon 33-125 GGAATTCACCCATCTACAGTCC 317 bp # 
4R GGAATTCAGGGCAACTGACCGT 
p 
on 5 5L codon 126-186 TGTTCACTTGTGCCCTGACT 223 bp ^ 137 
5R AGCAATCAGTGAGGAATCAG 
tji 
如 6 L codon 187-224 TGGTTGCCCAGGGTCCCCAG 135 bp 137 
6R GGAGGGCCACTGACAACCA 
� ” 7L codon 225-260 CTTGCCACAGGTCTCCCCAA 151 bp 137 
7R AGGGGTCAGCGGCAAGCAGA 
包Xo 
“ 8 L codon 262-306 TTGGGAGTAGATGGAGCCT 174 bp 137 
8R AGTGTTAGACTGGAAACTTT 
：^；；；^  
杯 Ol^d 仗 means upstream and downstream primers respectively. 
� q = t ( j A，Smeshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J. 
C咖Pf 二 ic losses and mutation of the p53 in Human ovarian cancer, 
er Res 51:5171-5176，1991. 
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(5000Ci/mmol) (Amersham). 
A pair of upstream and downstream primers flanking the exon of p53 gene 
(5pmole each) was phosphorylated with 5 ul of [y-^^P]ATP by 10 units of T4 
polynucleotide kinase*� in a total volume of 10 ul phosphorylation reaction buffer"^^ 
incubated at 37°C for 30 minutes. These amount of radioactive labeled primers was 
enough for amplifications of target sequence in 40 DNA samples. 
Amplification of target sequence by Polymerase Chain Reaction 
The GeneAmp™ Polymerase Chain Reaction (PGR) kit^ ^ (Perkin-Elmer Cetus) 
Was used in this study for in vitro amplification of target sequence. 
The radioactive labelled primers solution was diluted with 105 ul of autoclaved 
double distilled water. In the PGR reaction mixture for 40 DNA samples, 20 ul of lOX 
PCRbuffer48 and 5 ul of 2.5 mM deoxyribonucleotide triphosphates (dNTPs) mixture^^ 
Was added. After addition of 5 units of AmpHTaq'^^^A polymerase^®, 4 ul of this 
PCR reaction mixture was aliquoted to forty 0.5 ml thin walled PGR tubes containing 
加(about lOOng) of genomic DNA sample as DNA template in each tube and then 
^ drop of mineral oil was added to prevent from evaporation. The PGR was carried out 
in a DNA Thermal Cycler (Perkin-Elmer Cetus) under the following conditions: the 
template DNA was first denatured by incubation for 5 minutes at 95°C, followed by 
40 cycles of PGR (1 min. incubation at 60�C for annealing; 30 seconds at 72�C for 
Polymerization; and 30 seconds at 94°C for denaturation). For amplification of exon 
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6 of p53 gene, the annealing temperature was 58°C in the 40 cycles of PGR. 
8.3. Nondenaturing Polyacrylamide Gel Electrophoresis 
In nondenaturing conditions, single-stranded DNA has a folded structure that is 
determined by intramolecular interactions in the nuleotide sequence. Different size and 
shape as well as its surface charge density of this particle caused different mobility in 
� 
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tile nondenaturing polyacrylamide gel electrophoresis (Model S2, BRL). 
Before electrophoresis, the 5 ul of PGR product was mixed with 45 ul of 
loading buffer^^ and denatured by heating at 95°C for 10 minutes and chilling on ice. 
2 ul of the denatured sample was loaded on a 40-cm 8 % polyacrylamide (BRL)(49:1, 
acrylamide:N,N'-methylenebisacrylamide)/0.5X TBE gel and ran at 30 watts 
(Pharmacia LKB-ECPS 3000/150) at 4°C for 4 hours using 0.5X TBE as 
electrophoresis buffer. In the second electropho^^ and ran at 1.5 watts at room 
temperature for 18 hours. For the PGR product of exon 4 of p53 gene, no room 
temperature gel was run but the samples was electrophoresed in the gel with glycerol 
at 30 watts at 4�C for 6 hours. In addition, the cold room gel electrophoresis with 
glycerol as exon 4 was performed for the exon 7 of p53 gene. 
Finally, the gel was transferred onto Whatman 3MM No. 1 paper and dried up 
Using gel dryer (Model SEl 160, Hoefer Scientific Instruments) . Autoradiography was 
performed using an intensifying screen and an exposure of 12-48 hours at room 
temperature. 
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8.4. Direct DNA sequencing of PGR products with p53 mutation 
Abnormal band detected by SSCP analysis were excised from the dried gel, 
placed in 50 ul of autoclaved double distilled water, and incubated at 65�C for 6 hours. 
Supposingly, only PGR products from p53 mutated allele can be obtained. After 
centrifugation at 16000 rpm for 10 minutes (Micro Centaur, MSE), 10 ul of 
supernatant was collected for re-amplification of this eluted DNA with the 
corresponding sets of primers using the same conditions as described above in a total 
volume of 100 ul. Following 6 % polyacrylamide (29:1, acrylamide:N,N'-
«iethylenebisacrylamide)/lX TBE gel electrophoresis (Model VI6-2, BRL), the slice 
of gel with re-amplified PGR product was cut, minced and soaked in 500 ul of TE pH 
7.5 overnight at 37°C to release the DNA from the gel. In order to prevent 
contamination of gel in the DNA sequencing reaction, the supernatant was used for 
^ ^ A extraction by phenol/chloroform method after spinning down all the minced gel. 
the re-amplified PGR product was then precipitated by 2 volume of absolute ethanol 
at -20�C. The DNA pellet was dissolved in 20 ul of autoclaved double distilled water. 
This purified DNA was ready to be used for direct DNA sequencing using 
ATaq™Cycie-Sequencing kit^ ^ (United States Biochemical). 
For direct DNA sequencing, either upstream or downstream sequencing primer 
of the corresponding exon of the p53 gene was radioactive labelled by 5'-end labelling 
kit as above. No sequencing primer was used for exon 4 and the primers for the 
Sequencing reaction was the primers for PCR-SSCP analysis. The sequencing primers 
Used for exons 5-8 were also purchased from Genosys Biotechnologies Inc. and listed 
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in table 8 (next page). The labelled primer was diluted one fold by autoclaved double 
distilled water before addition to sequencing reaction mixture. 
In the cocktail of DNA sequencing reaction mixture, 1 ul of radioactive labelled 
primer was mixed with 2 ul of re-amplified PCR product as template DNA, 2 ul of 
Reaction Buffer^'^ and 2 ul of ATaq version 2.0 solution^^ in total volume of 17 ul. 
Then 4 ul of this cocktail was aliquoted to 4 termination tubes. Each tube contained 
4 ul of one of Termination Mix^^ For example, the ”G" labelled termination tube was 
filled with 4 ul of ddGTP Termination Mix. The evaporation of reaction mixture was 
also prevented by addition of a drop of mineral oil to each tube. The termination 
reactions carried out in a DNA Thermal Cycler using the same conditions for PCR-
SSCP analysis. 
The addition of 4 ul of stop solution^'' was followed to stop the termination 
reaction. Finally, the sample was boiled for 10 minutes and 2 ul of it was immediately 
loaded on the 8 % sequencing geP^ which was pre-run at 1700 voltages for 30-60 
minutes until 6(fC was reached. After electrophoresis at 1700 voltages for 2 hours, the 
Sequencing gel was blotted onto Whatman 3 MM no.l paper, dried in gel dryer and 
exposed to Kodak Diagnostic film (Eastman Kodak Co.) at room temperature for 12-48 
hours with an intensifying screen. 
8 Controls 
Unfortunately, there is no positive control (i.e. no mutation in this exon in the 
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^^Table 8 ： p53 exons 5-8 sequencing primer sequences for Direct DNA Sequencing 
^^^^^ n^e?* Nucleotide Sequence ref 
Bxon ^ 
^ 5US TTCAACTCTGTCTCCTTCCT 137 
5DS CAGCCCTGTCGTCTCTCCAG 
6US GCCTCTGATTCCTCACTGAT 137 
6DS TTAACCCCTCCTCCCAGAGA 
‘ 7US AG G CG CACTG G C CTC ATCTT 137 
7DS TGTGCAGGGTGGCAAGTGGC 
^ 8US TTCCTTACTGCCTCTTGCTT 137 
^ 8DS AG G C ATAACTG C ACCCTTG G 
DS nieans upstream and downstream sequencing primers respectively. 
the pS义OLsequendng the PCR-amplified DNA fragment ofexon 4，the same primers for 
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avaiable materials was found before this study) for PCR-SSCP analysis on exons 5 and 
Only the analyses on exons 4, 7 and 8 had positive control. These included: a 
cervical carcinoma containing nucleotide change from GCT to GTT at codon 63 (226), 
a brain tumor with mutation at codon 245 (GGC to AGC) (unpublished data) and one 
nasophagneal cell line CNE-1 which is known to have nucleotide change from AGA 
to ACA at codon 280 (227). 
IV.9 PGR method for Detection of Human Papillomavirus (HPV) 
PCR-Amplification 
Oligonucleotide primer pairs,purchased from Genosys Biotechnologies Inc., were 
chosen to amplify 360-，152- and 216- base pair sequences within the LI gene of HPV 
U，HPV 16 and HPV 18 respectively (Table 9, next page). For detection of HPV 6 
and HPV 33, the 280base pair sequence within E5 gene and the 455 base pair sequence 
Within E1/E2 gene respectively were amplified. The primers for the reference gene 
Sequence amplified a 268 base pair fragment (Table 9, next page). All primer 
sequences were taken from the published sequences (228). The GeneAmp™-PCR kit^ ^ 
Was used. The PGR reaction mixture contained 50 mM potassium chloride 10 
_ Tris-HCl PH8.361，7 mM magnesium chloride (MgCl�/"，400 uM deoxynucleotide 
triphosphates (dNTPsp, 0.32 uM of each primer and 2 units of AmpliTaq^^-
Polymerase'' in a 50 ul total volume. The PGR was performed for 40 cycles in a 
System 9600 (Perkin-Elmer Cetus) using 3-steps programs for HPV 
6 and beta-globin and 2-steps programs for HPV 11，HPV 16，HPV 18 and HPV 33 
listed in Table 10 (page 73). 
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Table 9 ： HPV 6，11，16，18 and 33 Primers and Oligonucleotide Probe Sequences 
_ 
w Primers 
Virus type Localization Nucleotide Sequence PGR product size 
HPV 6 4671-4690 TAGTGGGCCTATGGCTCGTC 
4931-4950 TCCATTAGCCTCCACGGGTG 280 bp 
HPV 11 6841-6860 G G AATACATG CG CC ATGTG G 
D 7181-7200 CGAGCAGACGTCCGTCCTCG 360 bp 
HPV 16 6029-6048 TG CTAGTG CTTATG CAG CAA ‘ 
T 6160-6179 ATTTACTG CAACATTG GTAT 152 bp 
HPV 18 6903-6922 AAGGATGCTGCACCGGCTGA 
, 7100-7119 CACGCACACGCTTGGCAGGT 216 bp 
HPV 33 2415-2434 ATGATAGATGATGTAACGCC 
2851-2870 G CACACTCCATG CGTATCAG 455 bp 
3-globin GAAGAGCCAAGGACAGGTAC 
� CAACTTCATCCACGTTCACC 268 bp 
JJPV 6 4761-4790 CATTAACGCAGGGGCGCCTGAAATTGTGCC 
gJV 11 6978-7007 CG CCTCC ACCAAATG GTACACTG G AG G ATA 
S^V 16 6117-6147 GCAAACCACCTATAGGGGAACACTGGGGCA 
g j V 18 7021-7051 TGGTTCAGGCTGGATTGCGTCGCAAGCCCA 
^N^i^gV 33 2560-2590 CAAATGCAGGCACAGACTCTAGATGGCCAT 
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Table 10: PGR conditions for detection of HPVs and Beta-globin gene 
Denaturation Annealling Extension 
PCR no.of cycles 
» 
Temp./ Time Temp./ Time Temp./Time 
I 
HPV6 40 94�C/ lmin 64�C / 2mins 72°C /2mins 
HPV 11 40 94T / Isec 56°C / 5 sec - / -
HPV 16 40 94°C / Isec 42°C / Isec - / ' -
HPV 18 40 94°C / Isec 50�C / Isec - / -
HPV 33 40 94°C / Isec 56°C / 5 sec - / -
, Beta-globin 40 94�C / 30sec 57�C / 30sec 72�C/lmin 
I "" 
fotes: Before entering the cycles, all the mixtures were heated at 94°C for 5minutes. 
Moreover, in the last cycle, the extension step was extended for 10 minutes. 
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After PGR, 25 ul of the PGR products were electrophoresed on 3 % agarose gel 
(3:1，wide range : standard agarose)(Sigma) containing 0.5 ug/ml ethidium bromide at 
100 voltages for 2 hours using IX TBE as electrophoresis buffer in a horizontal gel 
electrophoresis system. The photograph was taken under UV illumination. 
9.2. DNA Alkali Blotting Technique 
The PGR products were transferred onto Hybond-N+ membrane for—fiiture 
hybridization as Southern blotting technique as above but instead of 20X SSC，0.4M 
NaOH solution was used as blotting buffer. Moreover, there was no need to fix DNA 
by alkali fixation after blotting. 
Preparation of Radioactive labelled Oligoprobes 
The oligoprobes representing regions internal to the amplified sequences, were 
labelled with [y-^^PJATP by using 5'-end labelling kit. Briefly, 12.5 picomole of 
oligoprobe was reacted with [y-^^PJATP in the presence of 10 units of T4 
Polynucleotide kinase in 25 ul of total volume of phosphorylation buffer at 37°C for 
30 minutes. The radioactive labelled oligoprobe was mixed with 25 ul of sonicated 
Salmon sperm DNA (250 ug/ml)(Sigma) and the mixture of DNA was precipitated by 
addition of 37.5 ul of 5M ammonium acetate and 175 ul of freezed absolute ethanol 
at -70°C for 2 hours. After centrifugation at 16000 rpm for 20 minutes in Batch-top 
Microcentrifuge, the DNA pellet was dried and then dissolved in 100 ul of TE pH 8.0. 
Hybridization of DNA Blots with Radioactive labelled Oligoprobes 
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The procedure of this hybridization was similar to that for hybridization analysis 
in above. The pre-hybridization^^ and hybridization solutions^^ in this section contained 
no formamide and the temperature for incubation was 37°C instead of 42°C. After 2 
days hybridization, the DNA blots were washed with 2X SSC at 3TC for 15 minutes 
twice and then with 0.5X SSC/0.1 %SDS at 55�C for 30 minutes once. Finally, the 
Washed DNA blots were wrapped by Saran-Wrap™ Brand Plastic Film and then 
exposed to X-ray film (Kodak Diagnostic) at -70�C for 3 hours in the presence of 
intensifying screen. 
9.5. Controls 
Two cervical cancers (226) proved by PGR method to have either HPV 16 or 
HPV 33 infection were used as positive controls for detections of HPV 16 and HPV 
33 in this study. For HPV 6 and HPV 11，the positive controls were the whole 
genomes of HPV 6 and HPV 11 cloned in the plasmid pBR322. The DNA from Hela 
cell line known to be HPV 18 infected acted as positive control for detection of HPV 
18. Reagent control was done in every amplifications to prevent false positivity due 
to contamination of viral DNA in the reagents. . 
9.6. Sensitivity of HPV 18 detection by PCR method 
Sequential diluted Hela cell line DNAs (0.05ng, 0.5ng, 5ng，50ng, 500ng and 
5000ng) were subjected to PCR-amplification for detection of HPV 18. 
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V. R E S U L T S 
V.l. Grading and Staging of Prostatic Carcinoma in 18 patients 
All 18 patients have the acinar type of adenocarcinoma with none having 
features of variants such as small cell carcinoma, neuroendocrine and endometrioid 
differentiations. The mean age of the 18 patients was 72.8 years (Table 11’ next page). 
All patients presented with symptoms of prostatism which included frequencies, dysuria 
and noctiuria. 14 patients underwent transurethral resection of prostate (TURP) for the 
first time because of these presenting symptoms and 8 patients clinically were 
suspected to have carcinoma before pathology confirmation. The remaining 4 patients 
Were known for prostatic carcinoma, had bilateral orchiectomy and were under 
treatment with Flutamide, an anti-androgen agent, at the time when TURP specimens 
Were studied (Table 11，next page). 
The predominant histological pattern in 9 of the 18 patients was of Gleason 
grade 3 prostatic carcinoma (Figure 8，page 78). The predominant Gleason grading for 
the remaining patients was 2, 2，3 and 2 respectively for grades 1, 2, 4, and 5 (Table 
U，next page). The majority of patients had an intermediate Gleason with 2, 4 and 6 
Patients having a score of 5, 6 and 7 respectively. Only 2 patients had low Gleason 
Score with one patient each for score 2 and 3 (Figure 9, page 78). High Gleason score 
外ere observed in 4 patients with 1，2 and 1 having score of 8, 9 and 10, respectively 
(Figure 10，page 79). The 2 patient with low Gleason score had mild cytological atypia 
and classified as WHO 1，well differentiated carcinoma of prostate (Figure 9，page78). 
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Table 11. Clinical and p53 immunohistochemical Data of Prostatic Carcinomas 
feaaajj^^ 
Pt Age TBP Grade PSA Ab3 DOT D07M Stage F-UP# 
� (score) R 
61 0,C 3-3 (6) >100 - - + D DWD-7 
91 no 2-3 (7) NA - - • A H-15 
72 no 3-4 (7) NA + + NA’BS- AWD-9 
75 no 3-4 (7) >100 + D DWD-3 
, 5 6 no 2-3 (5) 61 - - - D H-20 .1 
-^gjggO 64 0，C 3-3 (6) >100 - + + D DWD-6 
86 no 4-4 (8) >100 - - ' D DWD-9 
72 0,C 3-3 (6) >100 + - + D DWD-8 
81 no 4-5 (9) NA + + + D no FU 
92S9105 66 no 5-5 (10) 30 + + + NA,BS- AWD-
I \ \2 
92S9654 72 0,C 3-4(7) >100 + - + D DWD-
I 、 10 
！ 92810458 82 no 3-4 (7) >100 + - + D AWD-, ^ 
j 74 no 1-2 (3) >100 D H-10 
^^ ^Hii^ TO 79 no 1-1 (2) 20 NA NA NA A H-13 
9找 11371 77 no 3-3(6) 99 - - + D AWD-
: ^ ^ n 
92S12103 72 no 4-3 (7) >100 + + + D AWD-
： ]0 
i 68 no 3-2 (5) 23 - + + D AWD-9 
63 no 5-4 (9) 29 - B H-8 
� P a r 
Or^ jj. le〒；TBP*: treatment before transurethral prostatectomy, with O = orchiectomy, C = chemotherapy. 
i fepj. ^^ is expressed by 2 values with the first representing the dominant growth pattern and the second • 
I c e n t s a second pattern, the Score is the sum of these 2 values. 
吻d j^^ti-mutant p53 antibody PAb240 (Oncogene Sciences) and D07: antibody recognizing both wild-type 
亡场bed以ant p53 proteins (Dakopatts). D07MR: Immunohistochemical staining on microwave treated paraffin 
Clinie d tissue sections. 
电 ed Staging is classified as A，B，C,D (see introduction). F-UP: follow-up, A WD: alive with disease, DWD: 
如财b ith disease, H: apparently healthy (absence of symptoms, normal examination, normal PSA levels), the 
^ that follows the clinical course represent the follow-up period expressed in months, 
rostate specific antigen in serum. 
I 
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Figure 8: Moderate differentiation of glands with cribiform pattern in Prostatic Carcinoma 
Figure 9: Well differentiated glands in Prostatic Carcinoma 
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Figure 10: Poorly differentated glands to Sheets of tumor cells in Prostatic Carcinoma 
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The remaining 16 patients exhibited moderate cytological anaplasia, WHO 2 (Figure 
8，page 78), however no cases examined demonstrated severe anaplasia, WHO 3. 
Clinical staging were assessed by means of rectal examination, CT scan of 
abdominal organs and bone scan. 13 patients at the time of studies were clinically stage 
D with positive bone scan and bone metastasis (Table 11, page 77). 5 patients have 
如mour confined to the organ on rectal examination, a negative bone scan and 3 of 
these were confirmed as stage A having a negative CT scan and 2 patients did not have 
a CT scan such that staging is incomplete (Table 11, page 77). 
17 of the 18 patients had a 3 to 20 months follow-up since this study started. 
^ patients are apparently healthy, that includes absence of symptoms, normal rectal 
examination and prostatic specific antigen levels after a mean follow-up period of 13 
Months (Table 11, page 77). Six patients died with the disease in the mean follow-up 
period of 7.3 months. Six other patients were alive with disease activity after a follow-
^P period of 11.7 months. 
� � 1 � P 5 3 immunohistochemistry in prostatic hyperplasia and carcinoma 
Of the 18 cases of prostatic carcinoma examined, 17 were studied since one 
specimen (93S11370) only had a few small clusters of well-differentiated carcinoma 
and no malignant glands were present in the sections examined for 
Immunohistochemistry. For all immunohistochemistry, p53 antibodies, D07 and 
^Ab240, were used. Only the nuclear staining in the cancer cells was considered to be 
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positive, clearly distinct from the absence or weak background cytoplasmic staining in 
ttiese cells (Figure 11, next page). Moreover, these positive cases did not show any 
staining in stromal cells. For D07 immunostaining using frozen tissue sections, 5 out 
of 17 cases were positive (Figure 11, next page). It is slightly less than the frequency 
of positive immunostain for PAb240 with 7 positive out of 17 cases (Figure 12, page 
83). However, using microwave treated paraffin embedded tissue sections for D07 
immunostaining, 12 out of 17 cases (Figure 13, page 84) showed positive immunostain 
for D07 anribody. In contrast to prostate cancers, all benign prostatic hyperplasia we 
studied did not demonstrate any positive staining in the epithelial cells for p53. 
Surprisingly, some nuclear staining can be found in the basal cells of all cases of BPH 
(Figure 14，page 85) 
In the immunostaining using the antibody D07，the results of the 
immunostaining with the microwave antigen retrieval technique shows higher rate of 
positive staining as compared with the standard technique. All 5 cases positively 
stained for D07 with standard method are confirmed by the microwave antigen 
retrieval technique, which shows an additional 7 positive cases. A total of 7 specimens 
out of 17 stain positively for PAb240 and all correlate with a positive stain with D07 
妨tibody when the microwave antigen retrieval technique is used, while correlate 
poorly with D07 staining using standard technique (Table 11, page 77). 
Results of Hybridization analysis 
We examined pairs of somatic DNA (peripheral blood leukocytes) and tissue 
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figure 11： p53 immunohistochemistry using D07 antibody on Frozen tissue section of 
Prostatic Carcinoma. (UPPER- X40 LOWER-- XI00) 
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figure 12: p53 immunohistochemistry using PAb240 antibody on Frozen tissue section of 
Prostatic Carcinoma. (UPPER- X40 LOWER-- XI00) 
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figure 13: p53 immunohistochemistry using D07 antibody on microwave treated paraffin 
embedded tissue section of Prostatic Carcinoma. (UPPER-- X40 LOWER-- XI00) 
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Figure 14: p53 immunohistochemistry using D07 antibody on microwave treated paraffin 
embedded tissue section of prostatic hyperplasia. Arrow heads indicate the nuclear stained 
basal cells. 
85 
DNA (surgical specimens) from 18 carcinoma of prostate (CaP) patients and 25 benign 
prostatic hyperplasia (BPH) patients using a panel of three polymorphic DNA markers 
for loci on chromosome 17. These DNA markers were pYNZ22, php53B and pTHH59. 
pYNZ22 is homologous to locus D17S30 which is located at the short arm of 
chromosome 17 (17p) and is telomeric to the p53 gene and this locus contains a 
Variable number of tandem repeats (VNTR)(229). The other polymorphic DNA marker 
for the 17p is p53 gene cDNA probe, php53B. The homologue ofpTHH59 probe also 
contains a VNTR as pYNZ22 but this locus is located at the long arm of chromosome 
17(17q). Moreover, pUCEJ6.6 as a polymorphic DNA marker for the Ha-ras oncogene 
on the chromosome 11 was also employed in this study. 
The polymorphic DNA fragments digested with the restriction endonuclease 
Hinf l hybridized to the pYNZ22 probe were shown variable sizes depending on the 
number of tandem repeat in the fragments. All these fragments were less than 2 
kilobases. Twelve of 18 CaP cases showed heterozygous genotypes (i.e. 12 informative 
cases) by H i n f l digestion of DNA hybridized to the pYNZ22 probe (Table 12，next 
page). Because allelic loss was considered to have occurred when only one fragment 
remained for the tissue DNA in the presence of two different sized fragments for the 
leukocyte DNA of the same patient, the allelic loss was detected only in one sample 
of prostate cancer (92S10927) (Figure 15, page 88). In this case, the smaller 
polymorphic fragment was deleted. The remaining of the informative cases retained 
heterozygosity (Figures 16，17，18，pages 89,90,91)). For the BPH cases, eighteen out 
cases were informative. All these 18 cases demonstrated absence of allelic loss 
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Table 12: Hybridization analysis of prostatic lesions (CaP and BPH) 
^ ^ using probe pYNZ 22 and restriction enzyme Hinf I 
Diagnosis Total no. no. of informative no. of cases with no. of cases with % ofLOH/ 
^ ^ ^ of cases cases loss of heterozygosity retain of heterozygosity informative cases 
Cap 18 12 1 11 8.3 
：过 25* 18 0 18 0 
Although 30 cases of BPH were collected, a pair of blood and tissue samples was available for 25 cases. 
Table 13: Hybridization analysis of prostatic lesions (CaP and BPH) 
^ ^ nsinpi probe php53B and restriction enzyme Bgl n " 
h. 
'^ gnosis Total no. no. of informative no. of cases with no. of cases with %ofLOH/ 
^^^^^^^ of cases cases loss of heterozygosity retain of heterozygosity informative cases 
Cap 18 5 0 5 0 
^ 25* 11 0 11 0 
Although 30 cases of BPH were collected, a pair of blood and tissue samples was available for 25 cases. 
^ Table 14: Hybridization analysis of prostatic lesions (CaP and BPH) 
minp probe pUCEJ6.6 and restriction enzyme BamHI 
b‘ I I 
'^ ^Osis Total no. no. of informative no. of cases with no. of cases with %ofLOH/ 
of cases cases loss of heterozygosity retain of heterozygosity informative cases 
C a p ^ 
18 5 1 4 20 
S ^ ^ l ^ 25* 9 0 9 0 
�八1 如Ugh 30 
cases of BPH were collected, a pair of blood and tissue samples was available for 25 cases. 
V Table 15: Hybridization analysis of prostatic lesions (CaP and BPH) 
using probe pTHH59 and restriction enzyme Tag I 
k I P 
纽Osis Total no. no. of informative no. of cases with no. of cases with %ofLOH/ 
of cases cases loss of heterozygosity retain of heterozygosity informative cases 
P 18 5 0 5 0 
场 25* 4 0 4 0 
^ ^ 
hough 30 cases of BPH were collected, a pair of blood and tissue samples was available for 25 cases. 
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Figure 15: Autoradiograms of Hybridization analysis of CaP case (92S10927) 
DNAs from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
^dividual patients recognized by the variable number of tandem repeats polymorphic markers 
PYNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment, 
^ow-heads indicate the specific allele losses. 
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I i^gure 16: Autoradiograms of Hybridization analysis of CaP case (92S9105) 
I ^ NAs from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PVNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
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Figure 17: Autoradiograms of Hybridization analysis of CaP case (92S11370) 
^NAs from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PYNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
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figure 18: Autoradiograms of Hybridization analysis of CaP case (92S11371) 
I ^ NAs from TURP material and blood sample of the same patient were digested with 
Appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PYNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
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(Figures 19,20,21, pages 93,94,95). One representative BPH case showed homozygous 
genotype in Figure 22 (page 96). 
The p53 cDNA probe, php53B, detected Bgl II polymorphisms and two allelic 
fragments, 12 (allele 1) and 9 (allele 2) kilobases long, in addition to one constant 3-
kilobase band were detected (230). Using this probe, heterozygous genotype was found 
in five of 18 CaP cases and eleven of 25 BPH cases. However, all these informative 
cases including CaP and BPH showed retaining heterozygosity (Figure 16,21,22, pages 
89,95,96). The case of CaP detected to have an allelic loss (92S10927) was 
Unfortunately non-informative, and the two homologous chromosome 17 in the case 
contain allele 2 only (Figure 15，page 88). 
DNA extracted from five of 18 CaP cases and nine of 25 BPH cases showed 
one 7.2 kilobase fragment (allele 1) and one 6.6 kilobase fragment (allele 2) when 
digested with the restriction endonuclease BamH I and hybridized with a full-length 
probe for the Ha-ras oncogene, pUCEJ6.6. These heterozygous cases were considered 
to be informative. For the five informative cases of CaP, reduction to homozygosity 
in the tissue had been observed in one case (92S10927) which also showed allelic loss 
for pYNZ22 DNA marker (Figure 15, page 88). None of 9 informative BPH cases lost 
any allele (Figures 16,20,21,22, pages 89，94，95,96)(Table 14，page 87). 
Although the homologue of the pTHH59 probe contains a VNTR and exhibits 
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^gure 19: Autoradiograms of Hybridization analysis of BPH case (92S11920) 
D N A s from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
r eft of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
丨 PYNZ22 and pTHH59). 
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figure 20: Autoradiograms of Hybridization analysis of BPH case (92S10974) 
t>NAs from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PYNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
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figure 21: Autoradiograms of Hybridization analysis of BPH case (92S10975) 
E>NAs from TURP material and blood sample of the same patient were digested with 
] appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
i PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
Containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PVnZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
i 9 5 
N T 
A ‘ _ 
N T 1 mm 
1 H H ‘ 
Probe: pYNZ 22 3 藝 塞 
Enzyme: Hint I 學 
Probe: php53B 
Enzyme: Bgl II 
c IM T ° N T 
‘ _ _ 
,: . 豐 
I ‘ 
Probe: pUCEJ 6.6 Probe: pTHH59 
Enzyme: BamH I Enzyme: Taq I 
r 
Figure 22: Autoradiograms of Hybridization analysis of BPH case (92S10928) 
t)NAs from TURP material and blood sample of the same patient were digested with 
appropriate restriction enzymes and were analysed by Southern hybridization using the probes 
PYNZ22 (A), php53B (B), pUCEJ6.6 (C) and pTHH59 (D). The numbers (1 and 2) at the 
left of each panel refer to the larger and smaller restriction fragments, respectively, 
containing the alleles recognized by a given probe (different pairs of alleles are present in 
individual patients recognized by the variable number of tandem repeats polymorphic markers 
PYNZ22 and pTHH59). The number "3" represents an invariant 3 kb restriction fragment. 
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study. They were about 4 kilobase and 3.5 kilobase allelic fragments (allele 1 and 
allele 2) (Figure 17,18, pages 90,91). Of the 18 CaP cases, five cases as shown to be 
informative. Among these five informative cases, no allelic loss can be observed. Both 
allelic fragments were present in the pairs of DNA samples (leukocytic DNA and tissue 
DNA). Four of 25 BPH cases showed heterozygous genotype but no reduction to 
homozygosity was demonstrated in all these four informative BPH cases (Table 15, 
page 87). For the 92S10927 case (Figure 15，page 88)，homozygous genotype was 
shown and then whether the allelic loss of D17S4 Locus on the long arm of 
chromosome 17 in this case cannot be determined. 
V.4. PCR-SSCP findings in prostatic hyperplasia and carcinoma 
PCR-SSCP analysis was employed to screen DNA samples for changes in exons 
4, 5, 6, 7 and 8 in p53 gene, where mutational hot spots exist. The basis of this 
technique is that radiolabeled PGR products when denatured and allowed to renature 
in dilute conditions will assume an intramolecular secondary structure unique to that 
sequence. When these single-stranded PGR products were separated electrophoretically 
in non-denaturing polyacrylamide gel, different DNA sequences caused different 
Mobilities of these single-stranded PGR products. Therefore, mutant and normal p53 
genes can be distinguished. This analysis allows us to screen for mutations heavily 
diluted by wild-type sequences. 
In this study, PCR-SSCP analysis was performed by the amplification of the 
individual exons 4，5, 6，7 and 8 by using genomic DNA of sample as a template 
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(Table 16，next page). Polymorphic base substitution at codon 72 generated four bands, 
two pairs of single-stranded conformation, on the PCR-SSCP analysis of exon 4 
(Figure 23, page 100). This polymorphism was previously reported by Buchman et al 
(231). We sequenced this region and confirmed a base pair change from CCC 
(proline) to CGC (arginine) in codon 72 (Figure 24, page 101). Besides this 
polymorphism, the other mobility shifts in the exon 4 ofp53 gene was observed in one 
case of benign prostatic hyperplasia (92S10928) (Figure 23, page 100) but not in the 
patients with prostate cancer. The leukocytic DNA representing the germ line status of 
this case also showed extra band with altered migration as the tissue DNA. These extra 
bands were isolated and reamplified, and their nucleotide sequence was determined in 
order to identify the mutation by direct DNA sequencing analysis. It was found that 
this case revealed a missense mutation at codon 63 involving a change in nucleotide 
sequence from GCT to GTT and residue from arginine to cysteine (Figure 25, page 
102). 
PCR-SSCP analysis of exon 5 revealed abnormal migration in one case of 
prostatic cancer (92S9105) (Figure 26, page 103) but not in benign prostatic 
hyperplasia. In contrast to case 92S10928, this abnormality only was found in tissue 
^NA but not in the same patient's leukocytic DNA. This aberration suggested that p53 
Mutation in this exon was unique and intrinsic to prostate cancer cells in this case. This 
specific case's PCR-amplified region with mobility shift was sequenced and was shown 
to have a missense mutation changing from CGC to CAC. The encoded amino acid 
residue at this codon was converted from histine to arginine (Figure 27, page 104). In 
98 
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Table 16: PCR-SSCP analysis of exons of p53 gene in prostatic lesions 
^ — 
^ ^ , no. of cases with mobility shifts 
^^ lagnosis Total no. ： 
^ of cases Exon 4 Exon 5 Exon 6 Exon? Exon 8 
CaP 18 0 r 0 0 0 
如 H 30 0 1# 0 0 
l > ； 
. � O n l y tissue DNA showed mobility shift in the PCR-SSCP analysis. 
�Both tissue DNA and the same patient's leukocytic DNA showed mobility shifts in the PCR-SSCP 
analysis. " 
Table 17: Detection ofHPV infection in prostatic tissues by PGR method 
^ 
h； rp ‘ 1 no. of cases with HPV infection 
…agnosis Total no. 
^ ^ ^ of cases HPV 6 HPV 11 HPV 16 HPV 18 HPV 33 
Cap 18 0 0 0 0 0 
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Figure 23: SSCP autoradiograph of exon 4 of p53 gene 
Genomic DNA was amplified by PCR in the presence of 5，end labelling primers, denatured 
and run on a 8 % polyacrylamide gel at 4°C (A) and a 8 % polyacrylamide gel containing 
glyceral at 4°C (B). There are 16 representative cases, 5 prostate cancers (case nos. 1, 2, 5, 
13，14) and 11 benign prostatic hyperplasias (case nos. 3，4，6, 7，8，9，10，12, 15，16). The 
^'CR-amplified DNA from the tissue 
and blood samples of the case 6 (92S10928) showed 
extra bands. 
case 1 - 92S9105 case 2 - 92S9465 case 3 - 92S10481 case 4 - 92S10659 
case 5 - 92S10927 case 6 -- 92S10928 case 7 -- 92S10973 case 8 - 92S10974 
case 9 - 92S10975 case 10 -- 92S10995 case 11 - 92S11285 case 12 - 92S11369 
case 13 -- 92S11370 case 14 - 92S11371 case 15 - 92S11507 case 16 - 92S11920 
+ve control- a cervical carcinoma with nucleotide change GCT to GTT at codon 63 
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I i^gure 24: Sequencing autoradiograph of polymorphic site of exon 4 of p53 gene 
Sequencing autoradiogram showing polymorphic Acc II restriction site at codon 72 of alleles 
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I i^gure 25: Sequencing autoradiograph of exon 4 of p53 gene 
Sequencing of mutated exon 4 of p53 gene in benign prostatic hyperplasia. Portions of the 
sequence of the sense strand of exon 4 in the case 6 (92S10928) is shown. Both the tumor 
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Figure 26: SSCP autoradiograph of exon 5 of p53 gene 
Genomic DNA was amplified by PGR in the presence of 5'end labelling primers, denatured 
and run on a 8 % polyacrylamide gel at 4�C (A) and a 8 % polyacrylamide gel containing 
glyceral at room temperature (B). There are 16 representative cases, 5 prostate cancers (case 
nos 1 2 5 13 14) and 11 benign prostatic hyperplasias (case nos. 3，4，6，7, y’ lu，iz, 
15 '16，）The case 1 (92S9105) demonstrates the mobility shift for the tissue DNA but not in 
= i e l f G g = ， = V ! t i : ease 3 - 9 2 謹 8 1 case 4 - 92S10659 ea：： - ?S 27 case 6 — 92S10928 case 7 - 9 2 = case 8 - 9 ; 4 
case 9 - 92S10975 case 10 - 92S10995 case 1 - 92S 285 case 12 - 92S 369 
case 13 - 92S11370 case 14 - 92S11371 case 15 - 92S11507 case 16 - 92S11920 
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Figure 27: Sequencing autoradiograph of exon 5 
Identification of a point mutation in the exon 5 of p53 gene of prostate cancer (92S9105). At 
codon 175, the nucleotide ssequence CGC in normal DNA was changed into CAC in the 
tumor (92S9105) DNA. 
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addition, one information about the sensitivity of PCR-SSCP analysis was determined. 
When the denatured PCR product was run at 4�C in 8% polyacrylamide gel, the extra 
band was difficult to be identified (Figure 26A, page 103). However, the clear extra 
bands were shown in certain condition of PCR-SSCP analysis (at room temperature in 
8% polyacrlamide gel with glycerol (Figure 26B, page 103). 
For the PCR-SSCP analysis of exon 6，one case of benign prostatic hyperplasia 
and none of prostate cancer exhibited a'mobility shift. Moreover, the blood sample of 
this benign prostatic hyperplasia case also showed this altered migration (Figure 28， 
next page). After direct DNA sequencing of this PCR-amplified region with altered 
migration, it was found that the base substitution was not involved in the exon 6 but 
this was an intronic mutation changing the nucleotide from G to C at 17 bp 
downstream of 3，end of exon 6 (Figure 29, page 107). 
Abnormal migrations in exon 7 (Figure 30, page 108) and exon 8 (Figure 31, 
page 109) was only detected in the 2 positive control cases, one brain tumor sample 
and one cervical cell line (CNE-1) respectively, but not in any cases of CaP or BPH. 
I 
I Sequencing analysis of these two samples revealed the brain tumor was identified to 
contain mutation at 245 codon with a nucleotide change from G to A and CNE-a cell 
line had the mutation at codon 280 with a transversion from G to C. None of prostate 
lesions including prostatic carcinoma and hyperplasia showed any abnormality in these 
two PCR-SSCP analysis of exon 7 and exon 8. This indicated any p53 mutation within 
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Figure 28: SSCP autoradiograph of exon 6 of p53 gene 
Genomic DNA was amplified by PGR in the presence of 5，end labelling primers, denatured 
and run on a 8 % polyacrylamide gel at 4°C (A) and a 8 % polyacrylamide gel containing 
glyceral at room temperature (B). There are 16 representative cases, 5 prostate cancers (case 
nos. 1，2，5，13，14) and 11 benign prostatic hyperplasias (case nos. 3，4，6，7，8, 9，10，12， 
15, 16). Extra bands can be found only in the tissue and blood samples of the case 16 
(92S11920). 
case 1 - 92S9105 case 2 -- 92S9465 case 3 -- 92S10481 case 4 -- 92S10659 
case 5 - 92S10927 case 6 -- 92S10928 case 7 -- 92S10973 case 8 - 92S10974 
case 9 - 92S10975 case 10 -- 92S10995 case 11 -- 92S11285 case 12 -- 92S11369 
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Figure 29: Sequencing autoradiograph of intron 6 Sequencing of the intron 6 for the PCR-amplified DNA samples from tissue and blood of b nign prostatic yperplasia patient (92S11920). The nucleotide sequences demonstrate a basesubstitut n from g to c at the 17 bp downstream of 3' end of exon 6 when compared to th  normal tron 6 nucleot de sequ nce. 
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figure 30: SSCP autoradiograph of exon 7 of p53 gene 
Genomic DNA was amplified by PGR in the presence of 5'end labelling primers, denatured 
and run on a 8 % polyacrylamide gel at 4�C (A) and a 8 % polyacrylamide gel containing 
glyceral at room temperature (B). There are 16 representative cases, 5 prostate cancers (case 
nos. 1，2，5，13, 14) and 11 benign prostatic hyperplasias (case nos. 3，4，6，7，8，9，10，12， 
15, 16). No mobility shift for this exon is present in all the representative cases, except the 
+ ve control case, and even all cases we studied showed no mobility shift, 
case 1 - 92S9105 case 2 - 92S9465 case 3 -- 92S10481 case 4 -- 92S10659 
case 5 - 92S10927 case 6 -- 92S10928 case 7 -- 92S10973 case 8 - 92S10974 
case 9 - 92S10975 case 10 -- 92S10995 case 11 - 92S11285 case 12 - 92S11369 
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Figure 31: SSCP autoradiograph of exon 8 of p53 gene 
Genomic DNA was amplified by PGR in the presence of 5'end labelling primers, denatured 
and run on a 8 % polyacrylamide gel at 4°C (A) and a 8 % polyacrylamide gel containing 
glyceral at room temperature (B). There are 16 representative cases, 5 prostate cancers (case 
nos. 1，2, 5，13, 14) and 11 benign prostatic hyperplasias (case nos. 3，4，6’ 7，8，9, 10，12， 
15，16). As the analysis of exon 7, only the +ve control (CNE-1) showed a mobility shift 
but not in prostatic samples. 
case 1 -- 92S9105 case 2 -- 92S9465 case 3 - 92S10481 case 4 -- 92S10659 
case 5 - 92S10927 case 6 -- 92S10928 case 7 -- 92S10973 case 8 - 92S10974 
case 9 - 92S10975 case 10 -- 92S10995 case 11 -- 92S11285 case 12 - 92S11369 
ease 13 - 92S11370 case 14 - 92S11371 case 15 -- 92S11507 case 16 - 92S11920 
+ve control - CNE-1 
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v . 5 . PGR detection of HPV in human prostate 
In order to investigate the DNA quality of the samples for PGR amplification 
efficiency, the amplification of Beta-globin gene sequence by PGR method was 
performed. All the samples we studied showed the success of Beta-globin gene 
amplification. A representative photograph of our results from eight individual cases 
of prostatic lesion including cancer and hyperplasia is shown in Figure 32 (next page). 
In this study, the sensitivity of the PGR method for detection of HPV was 
determined by using the PGR method to amplifiy the LI gene of HPV 18 in a series 
of dilutions of DNA samples extracted from Hela cell line which was known to be 
infected by HPV 18 (Figure 33, page 113). It was found that the detection limit was 
O.OSng of Hela cell DNA. After electrophoresis of PCR product in the agarose gel with 
ethidium bromide, the distinct band representing the success of the LI gene of HPV 
18 was observed in the PCR mixture containing 0.5ng or above but not O.OSng of Hela 
cell DNA (Figure 34, page 114). The sensitivity of this method can be improved to 
detect HPV infection in the 0.05ngDNA sample of Hela cell by using radioactive 
labeled oligoprobe, in addition to increase the specificty of this method for detection 
i of HPV infection (Figure 33, page 113). 
I We examined 18 cases of prostate cancer and 30 cases of benign prostatic 
j 
hyperplasia in the detection of various types of HPVs by PCR method in this study. 
None of the 48 cases showed any convincing signal for the presence of various types 
of HPV DNA sequences in ethidum bromide stained agarose gels. Figures 35, 36, 37, 
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38 and 39，pages 115,116,117，118，119) demonstrated the results of the eight 
representative cases including prostatic carcinoma and hyperplasia in the detection of 
HPV 6, 11, 16，18 and 33 respectively. Even through Southern blotting analyses using 
radioactive labeled oligoprobes were employed, all the cases we studied was 
demonstrated no HPV infection (Table 17, page 99). The results of Southern blotting 
analyses using radioactive labeled oligoprobes of various types of HPV (HPV 6，11, 
16, 18 and 33) in the representative cases was shown in the Figure 40，41，42, 43 and 
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Figure 32: Polymerase Chain Reaction with human Beta-globin gene specific primers 
on DNA from Hela cell line as +ve control and on DNA from prostate tissues 
including 3 cases of prostate cancer (Lanes l,2and 5) and 5 cases of benign prostatic 
hyperplasia (Lanes 3，4，6，7and 8). 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 -- 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 -- 92S10974 
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Figure 33 : Autoradiogram of Southern blotting of PCR products obtained with 
specific human papillomavirus 18 LI gene primers and DNA from Hela cell line with 
series dilutions from 5000ng to 0.05ng. 
Lane 1 - 0.05ng Lane 2 - 0.5ng Lane 3 - 5ng Lane 4 - 50ng 
Lane 5 - 500ng Lane 6 - 5000ng 
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Figure 34: Agarose gel electrophoresis and ethidium bromide staining of PCR 
products obtained with specific human papillomavirus 18 LI gene primers and DNA 
from Hela cell line with series dilutions from 5000ng to 0.05ng. 
Lane 1 - O.OSng Lane 2 - 0.5ng Lane 3 -- 5ng Lane 4 - 50ng 
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Figure 35 : Detection of HPV 6 sequences in human prostatic tissues by PGR. 
Amplification products were resolved by agarose gel electrophoresis. The expected 
280 bp fragment is evident by ethidium bromide staining in +ve control only. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 - 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 一 92S10974 
+ve control -- HPV 6 carrying plasmid 
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Figure 36 : Detection of HPV 11 sequences in human prostatic tissues by PGR. 
Amplification products were resolved by agarose gel electrophoresis. The expected 
360 bp fragment is evident by ethidium bromide staining in +ve control only. 
Lane 1 -- 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 -- 92S10659 
Lane 5 - 92S 10927 Lane 6 - 92S10928 Lane 7 -- 92S10973 Lane 8 -- 92S10974 
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Figure 37 : Detection of HPV 16 sequences in human prostatic tissues by PCR. 
Amplification products were resolved by agarose gel electrophoresis. The expected 
152 bp fragment is evident by ethidium bromide staining in +ve control only. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 - 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 - 92S10973 Lane 8 -- 92S10974 
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Figure 38 : Detection of HPV 18 sequences in human prostatic tissues by PCR. 
Amplification products were resolved by agarose gel electrophoresis. The expected 
216 bp fragment is evident by ethidium bromide staining in +ve control only. 
Lane 1 - 92S9105 Lane 2 - 92S9465 Lane 3 -- 92S10481 Lane 4 - 92S10659 
Lane 5 -- 92S 10927 Lane 6 -- 92S10928 Lane 7 - 92S10973 Lane 8 - 92S10974 
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Figure 39 : Detection of HPV 33 sequences in human prostatic tissues by PCR. 
Amplification products were resolved by agarose gel electrophoresis. The expected 
455 bp fragment is evident by ethidium bromide staining in +ve control only. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 - 92S10481 Lane 4 - 92S10659 
Lane 5 - 92S 10927 Lane 6 - 92S10928 Lane 7 -- 92S10973 Lane 8 -- 92S10974 









Figure 40: A autoradiogram from blot of gel shown in Figure 35. 
Lane 1 - 92S9105 Lane 2 - 92S9465 Lane 3 -- 92S10481 Lane 4 - 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 - 92S10974 
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Figure 41: A autoradiogram from blot of gel shown in Figure 36. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 -- 92S10659 
\ Lane 5 - 92S 10927 Lane 6 - 92S10928 Lane 7 -- 92S10973 Lane 8 -- 92S10974 
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丨 Figure 42: A autoradiogram from blot of gel shown in Figure 37. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 -- 92S10481 Lane 4 -- 92S10659 
：L a n e 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 - 92S10974 
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Figure 42: A autoradiogram from blot of gel shown in Figure 37. 
Lane 1 - 92S9105 Lane 2 -- 92S9465 Lane 3 - 92S10481 Lane 4 -- 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 - 92S10974 
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Figure 44: A autoradiogram from blot of gel shown in Figure 39. 
Lane 1 - 92S9105 Lane 2 - 92S9465 Lane 3 - 92S10481 Lane 4 - 92S10659 
Lane 5 - 92S 10927 Lane 6 -- 92S10928 Lane 7 -- 92S10973 Lane 8 - 92S10974 
+ve control - a cervical cancer proved to have HPV 33 infection 
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VI. DISCUSSION 
In contrast to Western countries where the second most frequent cause of cancer 
death in males is prostatic carcinoma, in Hong Kong prostatic cancer is excluded from 
the list of ten leading cancer deaths in males (1,2,3,5 and Table 1, page 4). This 
marked difference in mortality due to prostatic cancer appears closely related to the 
nearly eight folds higher incidence of such cancer in Americans (42 per 100 000 males 
per year) when compared with the incidence of 5.6 per 100 000 males per year in 
Hong Kong Chinese (1,2,3,5). The role of environmental factors in prostatic 
carcinogenesis which include socio-cultural influences such as diet and sexual behavior, 
is demonstrated by epidemiology of prostatic carcinoma among the Asian immigrants 
/ 
in the United States (2,3,7,8). In this study, both carcinoma and nodular hyperplasia 
of prostate, as expected affect the elder geriatric population. The age distribution of 
both conditions are, similar with observation beginning after the age of 50 with an 
almost exponential increase after the age of 60 (Tables 2，page 6). The average age for 
both conditions is nearly identical at 70 year (Tables 2, page 6). Moreover, the annual 
prevalence of newly diagnosed cases of prostate cancer in Hong Kong between 1981 
and 1989 seemed increasing (Table 3, page 10). Although this increase in reported 
cases may in part reflect the increased aging population, there is also suggestion that 
tile incidence of prostatic carcinoma are slowly rising (Table 3，page 10). If acertained, 
such an observation may suggest and attribute the rise of prostatic carcinoma in Hong 
Kong to the Western socio-cultural influences and the changing of lifestyle of the 
Population. In the United States, ethnic black population has displayed a high rate of 
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prostatic cancer as well as a more aggressive disease as compared to white population 
(1,2,3,4). Since both populations have been exposed to the same environment, this 
indicates that genetic influences may have a role in the prostatic carcinogenesis (2,3,4). 
During the 18-month period of this study, only 18 cases of prostatic carcinoma 
were collected. Four of these patients were already known to have carcinoma of 
prostate and underwent TURP for obstructive symptoms and persistant or recurrent 
disease. They had previously bilateral orchidectomy and were receiving anti-estrogens 
at the time of study. The remaining 14 patients were newly diagnosed for prostatic 
carcinoma in surgical specimens. During the same period, 170 patients were diagnosed 
for nodular hyperplasia on TURP specimens, reflecting the relatively low incidence of 
prostatic carcinoma in our population. The average age of these 18 patients is 72.8 
year，which is similar to that of patients seen in this institution during the past 8 years 
(Table 2, page 6). Majority of the patients studied here have intermediate grade 
cancer, however 13 of the 16 patients with staging procedures showed advanced 
disease with evidence of bone metastasis and 9 patients had a markedly elevated serum 
level of prostatic specific antigen (Table 11，page 77). This study was thus carried out 
• 
m patients with advanced disease, 14 of whom had not received any treatment and 4 
after orchiectomy and hormonal treatment. During the study period, 6 patients died 
with disseminated disease, 6 other were alive with symptoms related to the cancer and 
5 patients were apparently clinically asymptomatic. All 18 prostatic specimens were 
histologically diagnosed as acinar type adenocarcinoma and 12 were of intermediate 
grade with a Gleason score of 5, 6 or 7. The consecutive 30 patients with prostatic 
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hyperplasia selected for this study had similar age with prostatic specimens similarly 
obtained through TURP. 
The tumor suppressor p53 gene and its mutations have been identified in a 
variety of human cancer, that include carcinoma of colon, breast, lung and brain 
(9,10,11,12,13,14). This work aimed at examining the p53 suppressor gene in prostate 
carcinoma and nodular prostatic hyperplasia by various molecular techniques to assess 
whether such gene may involve in the tumorigenesis of these two lesions in our 
population. 
In our immunohistochemical study of prostatic carcinoma (Table 11, page 77)， 
the antibody D07 with specificity for both wild-type and mutant p53 proteins in 
formalin-fixed paraffin showed 29% (5/17) immunoreactivity in frozen tissue section 
Which increased to 70% (12/17) with the microwave antigen retrieval technique on 
formalin fixed and paraffin embedded tissue section. Such a novel technique has 
recently been known to enhance the positive immunoreactivity both qualitatively and 
quantitatively (217,218,219). The mechanisms of such improved results by microwaves 
are not well-understood, but unmasking of hidden epitope by release of cross-linkage 
during microwave irradiation has been suggested (217,218,219). The antibody PAb240 
vvith specificity for mutant p53 protein demonstrated immunostain in 41% (7/17) of 
our cases in frozen tissues. Results for PAb240 in the literature vary according to series 
from 17% to 79% of prostate cancers (232,233,234). The result in this study (41%) do 
not compare favourably with them. For both D07 antibody on microwave treated 
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paraffin embedded tissue and PAb240 antibody on frozen tiisue the 
immunohistochemistry results were correlated in 70% of cases with 7 positive and 5 
negative immunostains (Table 11, page 77). 7 of the 12 specimens expressing DOT 
also stained with PAb240 indicating that mutant p53 protein accumulated in the tumor 
cells. The remaining 5 cases reflected the cellular accumulation of the wild-type p53 
protein. This finding opposes to the common view that wild-type p53 protein was 
usually undetectable because of a short life-span. This unexpected high level of wild-
type p53 proteins has also been reported in colorectal and lung cancer cell lines 
(17,235,236). The mechanism for such non-mutational stabilization of wild-type p53 
proteins is not yet known but it likely results from the interruption to the normal 
degradation of p53 proteins by mutation of another transforming gene and may 
possibly be implicated in the development of cancer (236). Alternately is that the 
presence of high level of wild-type p53 protein is due to overexpression by virtue of 
a mutation in the promoter or enhancer region of the gene which acts to increase 
expression. Previous studies using antibodies, CMl, PAblSOl, D07 or DOl, specific 
to both wild-type and mutant p53 protein showed that the rate of p53 positivity varied 
from 13% (237) to 14% (238) to 17% (239) to 20% (240,241) and up to 23% (242). 
In contrast , the percentage of p53 positivity was increased up to 70% in this study. 
It may be the result of microwave antigen retrieval procedure. Moreover, these studies 
also showed a correlation of positive expression with advanced Gleason scores. 
However, this correlation cannot be demonstrated in our study because both the groups 
of high-grade tumors (combined Gleason score of 7 or more) and low-grade (combined 
Gleason score of 3 to 6) showed about 70% p53 positivity (5/7 and 7/10 respectively). 
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Our result compared favourably with two studies by Soini and Foster (243,244) which 
also showed statistically insignificant association between p53 positivity and prostate 
tumor grade. 
5 of 17 cases showed negative immunostaining for both anti-p53 antibodies 
studied. If these are true negative results, the oversimplified view would be that no p53 
protein alteration was implicated in the carcinogenesis in these cases, but there are 
many potential reasons why p53 alteration cannot be detected immunohistochemically. 
Firstly, p53 gene mutations may lead to unstable mutant p53 proteins with a relatively 
short life-span so to escape detection (245). Secondly, some base pair change in p53 
gene may cause frameshift and stop codon, resulting respectively in abnormal 
conformation of mutant and in truncated p53 proteins, not containing the epitope 
recognized by the antibodies used (245). Finally, rare deletion of both p53 alleles in 
cancer cells causes absence of p53 protein production in some sarcomas (9). In 
immunohistochemistry, false negativity may be due to various technical factors 
including tissues fixation and processing, the specificity and the sensitivity of 
antibodies used. However, with good controls and techniques such a possibility was 
minimized. 
In immunoreactivity cases, only a proportion ranging from approximately 10% 
to over a half of cancer cells demonstrated the nuclear staining with varying intensity 
vvhich indicated the variation in nuclear p53 contents. Such heterogenous staining may 
represent p53 expressions of individual cancer cells in different stages of cell cycle. 
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Only at certain stages would the p53 protein expression be immunohistochemically 
detectable. Alternately, if unrelated to the cell cycle, the heterogenous p53 expression 
may suggest the possibility of two different clones of cancer cells, one exhibiting 
accumulation of p53 protein and the other lacking it. This hypothesis is indirectly 
supported by the observation of focal expression of p53 in a primary cancer cells but 
diffuse staining in metastatic ones (246). 
The prostate gland consists of relatively heterogeneous tissues and includes 
glandular epithelial cells, basal cells, fibromuscular stroma, and infiltrating 
lymphocytes. All these elements demonstrated negative staining for p53 and absence 
of p53 accumulation in these cells, with the exception of basal cells. Such negative 
findings are is in keeping with previous studies of p53 immunohistochemistry of 
benign prostatic hyperplasia (232,233,238,239,240,241,242,243). In basal cells of both 
prostatic hyperplasia and carcinoma, the expression of p53 protein with D07 antibody 
has not previously been reported. Although relatively weak, the staining is distinct and 
the possibility that there is really accumulation of mutant or wild-type p53 protein in 
the basal cells cannot be neglected. The increase in level of wild-type p53 protein can 
be considered to be the normal cellular response to DNA damage (100). Presumably, 
this response allows optimal repair of damage, before the cell reinitiates replicative 
DNA synthesis and/or begins mitosis or before initiation of S-phase. The use of a 
damaged DNA template during replicative synthesis could "fix" and propagate 
mutagenic lesions that might contribute to cellular transformation (27). The inhibition 
of replicative DNA synthesis, activation of mdm2 and growth suppressor genes and 
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repression of growth promotion genes by increasing the level of wild-type p53 proteins 
may be a critical step in avoiding the progressive increase in genomic changes that 
characterizes neoplastic transformation (88). The immunopositivity of prostatic basal 
cells may reflect the normal cellular response to DNA damage. Alternately, basal cells 
are regarded as the precusor of the prostatic glandular cells, the increase level of 
cellular p53 may be used to induce the differentiation of basal cells into glandular cells 
as the pathway of B-cell differentiation which wild-type p53 protein is known to'be 
the inducer (88). 
The specificity of PAb240 is supposed to react with the mutant p53 protein and 
not with the native wild-type p53 protein but instead recognizes a conformation epitope 
common to many mutant form of p53 protein (247). Therefore, using this monoclonal 
antibody in p53 immunohistochemistry can determine whether the wild-type or mutant 
p53 protein accumulated in the basal cells. In our results, some basal cells can be 
stained in nuclei. It indicated that the accumulated p53 protein in the basal cells are 
mutants. Recently, it was found that denaturation of the wild-type p53 protein could 
expose the epitope that PAb240 antibody detected (233). Additionally, conformation-
specific monoclonal antibody reactivity does not accurately reflect its wild-type or 
mutant status. Reactivity with both wild-type-specific and mutant-specific monoclonal 
antibodies has been shown to be due to interconversion between different p53 
conformations (248,249,250,251). Certain stimuli such as the induction of cell growth 
by extracellular mitogens can cause the conversion of wild-type p53 to an alternative 
Mutant conformation which can be recognized by PAb240 (245). Therefore, the 
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possibility of accumulation of wild-type p53 protein in basal cells cannot be excluded 
although there is immunopositivity of these basal cells by PAb240. 
From the results of p53 immunohistochemistry, p53 alteration such as 
mutation (both PAb240 and D07 positive) and stabilization (D07 positive but PAb240 
negative) may play an important role in the development of prostate cancer. However, 
while p53 gene mutation may lead to high level of cellular p53 expression, stabilization 
by non-mutational factors may lead to similar p53 accumulation (236). Such conclusion 
indicates the limitations of immunohistochemistry for the detection of p53 gene 
mutation including the immunopositive cases. Furthermore, the problem of false 
negative results may be reflected in our study by the enhanced expression following 
microwave antigen retrieval, highlighting the problem of antibody affinity, specificity 
and detection threshold intrinsic to immunohistochemistry. In this study of prostatic 
carcinoma, direct analysis of p53 gene is thus essential for the confirmation of p53 
mutation or of the possible stabilization of the wild-type p53 protein. 
Our initial molecular approach in the study of the p53 suppressor gene in 
prostatic carcinoma was based on the frequent association of an allelic loss with 
presence of mutation in the remaining allele (12,13,14,139). The study of 17p allelic 
deletion and p53 gene mutation in cancer of colon, lung, breast and brain have 
demonstrated this correlation (12,14,139). Therefore, we examined the loss of 
heterozygosity at the short arm of chromosome 17 and directly at p53 gene at first. 
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Hybridization of Hinfl-digested DNA isolated from peripheral blood 
lymphocytes and prostate tissue with hyperplasia or carcinoma from 43 patients with 
a pYNZ22 probe for a locus on 17p at 17pl3.3, D17S5 was used. Deletion at this 
region is currently regarded as the allelic loss ofp53 because the region 17pl3.3 is the 
closest to the p53 gene (252). In our study, 70% (30/43) prostate lesions, including 18 
prostatic hyperplasias and 12 prostate carcinoma were found to be informative for 
pYNZ22 (Table 12，page 87) a value slightly lower than 90%, the frequenc/ of 
heterozygosity reported in Caucasians (252). Only one patient of the 12 with carcinoma 
and none of the 18 with hyperplasia showed allelic loss at this region. This 8% (1/12) 
frequency of allelic loss at 17pl3 in our study is lower than that demonstrated by 
Carter with 17% (3/18) of prostate carcinoma (213). Such a slight difference in 
incidence may be explained the different probes used, as Carter used the probe pl44D6 
which recognizes the region 17pl3.0 while our probe pYNZ22 recognizes a similar but 
different region 17pl3.3 (213). Using the same pYNZ22 probe, Macoska also found 
6% (1/16 informative cases of prostatic carcinoma) with allelic loss (253). However, 
the case studied by Macoska is a late-stage poorly differentiated metastatic carcinoma 
with Gleason score 7-9，while our patient is a well-differentiated carcinoma with a 
Gleason score of 3 (case 92S10927). These 2 examples indicate that allelic loss at 
17pl3.3 region is relatively uncommon in carcinoma of prostate. Based only on two 
examples, a conclusion on the possible relationship between allelic loss at 17pl3.3 
region and prostatic cancer or its metastatic potential cannot be drawn and requires 
study of more examples. 
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This allelic loss at 17pl3.3 region is not observed in any of the 18 informative 
cases of nodular prostatic hyperplasia, suggesting that the development of prostatic 
hyperplasia is unrelated to this type of allelic loss. However, the tissue heterogeneity 
of the prostate glands which include epithelia, fibromuscular stroma and infiltrating 
lymphocytes, could conceivably "mask" the detection of allelic loss in the prostatic 
tissues, in particular when the predominant element in hyperplasia is fibromuscular 
tissue, despite careful selection to optimize epithelial content in our studied materials. 
Both Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-
RFLP) on locus YNZ22 and the CA-repeat polymorphism at 17p have overcome the 
problem of contamination by normal tissues in the study of allelic loss as only very 
small amount of DNA is sufficient for analysis (254,255). For these methods, the 
fibromuscular tissue were trimmed in sections, to optimize harvest of glands. These 
small amount of tissues in sections have enough DNA for analysis. An additional 
advantage of CA-repeat polymorphism analysis is that such method allows a higher 
yield of informative cases for study. 
Although the probe pYNZ22 which recognizes the D17S5 locus located at the 
17pl3 region was used for the study of p53 allelic loss, such a locus is still at several 
megabases telomeric to the p53 gene located at the 17p 13.1 region. Therefore, deletion 
detected at the locus D17S5 does not exactly or/and necessarily reflect the allelic loss 
of p53 gene (253). It was even suggested that p53 gene and D17S5 represent two loci 
putatively active in tumor suppression (253). Because of these considerations, we 
proceeded to direct p53 cDNA hybridization to exclude p53 allelic loss, a technique 
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which also provides informations on the macroscopic deletion and gene rearrangment 
in the tissues examined. 37% of cases we examined including 5 of 18 prostate cancers 
and 11 of 25 prostatic hyperplasia were informative (Table 13, page 87). These 
findings of p53 cDNA hybridization show that our Chinese population have a higher 
frequency of heterozygosity than Caucasians with a frequency of 15% and that ethnic 
difference in frequencies of heterozygosity may exist (256). However, using this p53 
cDNA probe, the only case of prostate carcinoma we demonstrated allelic loss by 
pYNZ22 was unfortunately not an informative case and thus the p53 allelic loss by 
cDNA cannot be confirmed in this example. Also similar to the results with pYNZ22, 
the p53 cDNA study reveals that all informative cases retain heterozygosity. This 
observation indicates that p53 allelic loss is not implicated and may not be important 
in the pathogenesis of both prostate cancer and hyperplasia. 
We also found no macroscopic deletion and gene rearrangment in the prostate 
lesions examined. This is consistent with the concept that inactivation of tumor 
suppressor gene p53 was infrequently due to macroscopic deletion and gene 
rearrangment and that these always involved in the activation of oncogene (257). 
However, rearrangement of p53 gene was observed in mouse erythroleukemias and in 
a few human tumors (57,127). 
Chromosome consists of 3 regions, the short arm (p) and long arm (q) of 
chromsome as well as centromere in between. When studying the allelic loss at 17p， 
the deletion of other arm must be studied to determine whether the whole chromosome 
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or one of the arms was deleted. We used the probe pTHH59 for the hybridization 
analysis to demonstrate the allelic loss at the long arm of chromosome 17，17q. 
Unfortunely, again the case of prostate carcinoma with allelic loss at 17pl3.3 region 
demonstrated by pYNZ22 was non-informative such that the portion of chromosome 
17 deleted in this case cannot be determined. Though the frequency of heterozygosity 
in Caucasians was found to be 79%, in our study only 9 out of 43 (21%) cases (Table 
14, page 87) examined were informative (5 prostate cancers and 4 prostatic 
hyperplasia). This relative small number of informative cases studied may not be 
sufficient to reflect the relation between allelic loss at 17q23-q25.3 region and prostate 
lesions, whether these be cancer or hyperplasia. 
The study of Ha-ras allelic loss by hybridization analysis using a probe 
pUCEJ6.6 revealed deletion of Ha-ras oncogene in 20 % of prostate carcinoma (1 out 
of 5 informative cases) but none of the 9 informative cases of prostatic hyperplasia. 
This single case of prostate cancer also carried allelic loss of D17S5 locus (Table 15, 
page 87). Similar to the p53 gene, allelic loss of Ha-ras oncogene in this example of 
prostate carcinoma may indicate the occurrence of Ha-ras gene mutation (258), Ha-ras 
gene mutation in prostatic carcinoma was reported to be 8% (2/24) by Carter and 16% 
(11/68) by Anwar, which appear relatively low (213,259). Besides the gene mutation 
leading to activation of Ha-ras oncogene, Ha-ras gene amplification and macroscopic 
deletion (i.e. deletion of first non-coding exon) were also reported to relate the 
activation of Ha-ras oncogene (260). In conclusion, our study based on 14 informative 
cases shows no evidence of Ha-ras gene rearrangement and macroscopic deletion in 
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prostatic cancer and hyperplasia. 
Our hybridization analysis indicate that in prostatic carcinoma and hyperplasia 
lacking immunohistochemical expression of p53 protein, there is no evidence of loss 
of p53 alleles, p53 gene rearrangement or macroscopic p53 deletion. The discrepancy 
observed between the frequent p53 immunoreactivity and the low incidence of allelic 
loss at 17p by hybridization, with reciprocal significance for p53 gene mutation 
requires further studies and confirmation by direct analysis of the p53 gene sequence. 
PCR-SSCP analysis has been reported to detect over 90% of all single base pair 
substitution, insertion and deletion in 200 nucleotide fragments and over 80% in 400 
nucleotide fragments (144,261,262). The mobility shifted PCR DNA product was 
directly sequenced to determine the site of mutation in the p53 gene sequence in our 
study of prostatic lesions. 
Only one case of prostate carcinoma (-6%, 1/18)demonstrated p53 gene mutation 
in the codon 175 of exon 5 where the base pair CGC was mutated into CAC and the 
corresponding amino acid in this codon was changed from arginine to histamine (Table 
16，page 99) (Figure 27，page 104). Although three of five prostate cancer cell lines 
(TSUPr-1, PC3 and DU145) (214) showed p53 gene mutation, the p53 gene mutation 
is a rare event of the primary prostate cancer. Only one case was found in this study. 
This result is quite consistent to the previous studies (263,264). The peripheral 
lymphocytes of the patient with this prostatic carcinoma demonstrated absence of this 
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p53 gene mutation and the mutation of p53 appears to be restricted to the cancerized 
organ. Although only a single example of p53 gene mutation is detected, the finding 
suggests that such mutation may be implicated in the development of prostatic cancer, 
at least for this case. Since the deamination of 5-methylcytosine can generate a C to 
T or G to A transition (265), this may represent one of the steps in the carcinogenesis 
in this patient. The codon 175 mutant allele is found commonly in colorectal 
carcinoma (8/25), Burkitt's lymphoma (3/40) and have been found at least once in 
breast carcinoma, glioblastoma and oesophageal carcinoma, biit not found in lung or 
hepatocellular carcinomas (14,142,138,144). In the transfection study of primary rat 
embryo fibroblasts, the codon 175 mutant was demonstrated to have highly 
transforming potential. The half-life of this codon 175 mutant protein was found to be 
3.6 hours which is longer than that of wild-type p53 protein (20 minutes) (154). While 
in this only case, the p53 point mutation in codon 175 correlates with accumulation of 
p53 protein in immunohistochemistry, many other examples with immunoreactivity for 
p53 did not show this correlation with SSCP studies. One explanation for this 
observation is that these tumors have high level of mutant proteins but harbor 
mutations outside of the studied regions of the gene. Of the 11 exons of the p53 gene, 
only exons 4 to 8 were analysed. However, mutations outside of exons 4 to 8 are rare 
in human tumors (10,266). Two studies of exon 2 through 11 in astrocytomas found 
no mutations outside of exon 5 through 8 (267,268), and only one astrocytoma has 
been documented with an intronic mutation (269) but only one with an exon 4 
mutation (270). 
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The discrepancy observed between immunohistochemistry and PCR-SSCP, that 
is positive immunostain and negative PCR-SSCP needs to be addressed. On one hand 
the discrepancy may be due to the limitations of immunohistochemistry already 
discussed or on the other hand may be due to the low sensitivity of PCR-SSCP method 
for detection of single base pair mutation. A number of variables that could play a role 
in the sensitivity of PCR-SSCP analysis include the size of the PCR product, the 
presence or absence of glycerol in the nondenaturating polyacrylamide gel, the 
temperature at which the gel was electrophoresed, the position of the base substitution 
within the fragment, and finally the sequence composition of the DNA fragment. All 
of these factors influence the secondary structure of the single-stranded DNA molecule 
(271). Increasing sensitivity of SSCP analysis is achieved by decreasing the size of the 
PCR product but there is likely a lower limit of size. The sensitivity of SSCP analysis 
of extremely small fragments is likely to be low due to constraints placed on the ability 
of a small fragment to form stable secondary structures. The optimal size fragment for 
sensitive base pair substitution detection by SSCP analysis is approximately 150 base 
pairs (271). Addition of glycerol also can improve the sensitivity of SSCP analysis. 
The reason of it may be that glycerol stabilizes the folded structure of single stranded 
DNA (271). Lower temperature also provides stabilization and higher sensitivity of 
SSCP analysis in gel electrophoresis (271). SSCP analysis for detection of p53 
mutation has shown that approximately 70 % of the mutations could be detected in a 
200 base pair fragment for the nondenaturing polyacrylamide gel electrophoresis at 
room temperature in the presence of glycerol (271). The addition of a second SSCP 
condition, 4 � C without glycerol, resulted in modest improvement (78%). We already 
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used both the above two SSCP conditions in order to improve the sensitivty of SSCP 
analysis but the discrepancy still occurred. Therefore, it is unlikely that sensitivity of 
SSCP analysis can totally account for the discrepancy between the immunopositive and 
SSCP-negative cases. 
Therefore, p53 protein accumulation without gene mutation may represent the 
actual character of the prostate cancer, similar to non-glioblastoma astrocytomas (272). 
Recently, Lane (273) established a new hypothesis for the stability of mutant p53 
protein in tumor cells. In the normal cells, the p53 protein level is low. When DNA 
damage occurs, the level ofp53 protein rises by post-translational stabilization in order 
to indure growth arrest for DNA repair or apoptosis for elimination of the DNA 
damaged cell. Finally, p53 protein level in surviving cell returns to normal. For the 
tumor cell with mutant p53 protein, no growth arrest or apoptosis occurs and 
stabilization continues. The high level of p53 protein was maintained in the tumor cell. 
Moreover, Barnes (274) discovered a novel cancer family syndrome where affected 
individuals accumulate high levels of wild-type p53 in normal tissues. The results 
suggested that these individuals inherit a dominant-acting aberrant gene that is unlinked 
to p553 and results in both the stabilisation of p53 proteins and the cell's ability to 
ignore its growth-suppressive effects. According to these, this aberrant gene may 
involve in the prostatic carcinogenesis and may lead to accumulation of wild-type p53 
protein in the prostate cancer cells. 
Two cases of prostatic hyperplasia showed p53 gene mutations by SSCP analysis 
and these were confirmed by direct DNA sequencing. A mutation GCT to GTT at 
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codon 63 in the exon 4 substituting alanine by valine in the p53 protein sequence was 
identified in one case. In contrast to the prostate cancer with exon 5 mutation, both 
tissue and blood samples of this benign prostatic hyperplasia case showed the exon 4 
mutation. This type of mutation 63^'' to can be found in one of human 
papillomavirus-negative cervical cancer reported by Lo and colleagues (226). The 
mutation may presumably disrupt p53 ftinction and the altered p53 may lead to the 
development of cervical cancer independently of human papilloma virus. Similarly, 
such a missense mutation suggests that alteration of p53 gene may have a role in the 
genesis of prostatic hyperplasia in our cases. Furthermore, the presence of the same 
mutation in the peripheral blood suggests a germline mutation and is associated with 
an increased risk for the disease as in Li-Fraumeni syndrome (148,149). 
Whether this germline mutation confers a high risk for prostatic hyperplasia 
remains to be determined. A systematic analysis of the biological properties of codon 
63 mutant p53 proteins must be undertaken to determine if the corresponding mutation 
has inactivated the p53 gene. Though no previous study demonstrated the biological 
properties of this mutant, this nucleotide substitution leads to conservative amino acid 
change (i.e. both alanine and valine are classified as nonpolar amino acid) and lies 
outside the conserved domains of p53 gene since there are five evolutionarily 
conserved domains, domain I (codons 13-19)，domain II (codons 117-142)，domain III 
(codons 171-181)，domain IV (codons 236-258) and domain V (codons 270-288). Even 
germline mutation which change the amino acid sequence in the conserved domains 
of p53 will not always be associated with an increased risk for early cancer, for an 
141 
example, mutation at codon 181 (275), it is most likely that a mutation at codon 63 in 
exon 4 substituting alanine by valine represents previously undetectable rare 
polymorphism, or variant without phenotypic expression. 
The AccII restriction site in exon 4 is well known for p53 gene polymorphism. 
This site is created by the shift of a C to a G, coding respectively for a proline or an 
arginine at codon 72. This polymorphism can also be demonstrated by SSCP analysis 
on exon 4. We found a 50% heterozygosity (i.e. containing one p53 allele with CCC 
at codon 72 and the other with CGC) in all our prostatic samples, frequency slightly 
higher than the 40% reported in Caucasians (276). This polymorphism has been used 
to directly detect loss of heterozygosity at p53 gene by PCR-RFLP analysis for other 
tumours. In this method, the PCR products of amplified nucleotide sequence in exon 
4 are digested by AccII restriction enzyme. The p53 allelic loss can be detected by 
agarose gel electrophoresis. An advantage of this method is the higher sensitivity or 
frequency of heterozygosity than hybridization analysis using p53 cDNA probe for Bgl 
II DNA digests. Another advantage is that DNA obtained from the formalin-fixed and 
paraffin-embedded archival tissues can be used, while only DNA from fresh tissue 
samples is suitable for hybridization analysis. 
In the other cases of prostatic hyperplasia with p53 mutation, intronic mutation 
(nucleotide change from G to C) was detected at 17 base pairs downstream of 3，-end 
of exon 6 in both tissue and blood. Previous reports suggested that intronic mutations 
of p53 gene were important in the inactivation of p53 ftinction and were detected in 
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various primary cancers and cancer cell lines (266). All of these intronic mutations 
were located at the donor and acceptor sites of RNA slicing could lead to a truncated 
p53 protein lacking part of carboxyl terminus. However, the intronic mutation found 
this case lies outside of both donor and acceptor RNA slicing sites. Therefore, this 
nucleotide difference at 17 base pairs downstream of 3'end of exon 6 can be 
considered to be a new rare polymorphism in p53 gene. 
In addition of the limitations of SSCP analysis for detection of p53 mutation, 
the contamination of normal cells in the hyperplastic prostate may masks the p53 
mutation. By SSCP analysis, mutations will not be detected unless they are in at least 
20% of the cells with mutated gene (277). Therefore, whether the accumulated p53 
proteins were wild-type or mutant cannot be determined in the p53 immunopositive 
prostatic basal cells because these basal cellsare only present in less than 20 % of cells 
in the prostate chip from which DNA was extracted for SSCP analysis. 
The wild-type p53 protein can bind to the E6 oncoprotein of human 
papillomavirus and the binding leads to degradation of p53 protein through the ATP-
dependent ubiquitin system (192). As a result, loss of p53 function may occur in the 
absence of p53 mutation. This correlation between absence of p53 mutation and human 
papillomaviurs infection can be found in cervical cancer (196,226). According to this 
correlation, whether p53 alteration does or does not involve in the development of 
prostatic lesion cases with p53 immunonegativity and even SSCP negativity cannot be 
determined. None of the prostatic lesion cases we studied did not demonstrate human 
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papillomavirus (HPV) infection by highly sensitive polymerase chain reaction method 
(Table 17, page 99). This indicates there is no relationship between p53 alteration and 
the development of prostatic lesions showing negative results in both p53 
immunohistochemistry and molecular analyses on p53 gene. We believe the results of 
our PCR method for HPV are truely negative, because the good quality of DNA 
samples was shown by their suitability for PCR reaction on beta-globin and the 
sensitivity of the method was controlled by detectable single Hela cell genomic DNA 
in the samples examined. 
The prevalence of human papillomavirus DNA in prostate tissue has been the 
focus of recent investigations. Many of these studies have reported conflicting results. 
Some PCR and Southern blots data have suggested that human papillomavirus DNA 
may be found in greater than 50% of malignant and non-malignant prostate tissue 
(259,278,279,280). Other investigators using PCR have found a much lower percentage 
(0 to 12%) of prostate cancer and benign prostatic hyperplasia specimens to contain 
human papillomavirus type 16 DNA and have suggested that urethral contamination 
of human papillomavirus may be a cause of false positivity (281,282,283). Our 
findings reveals no detectable human papillomavirus DNA in all 18 cases of prostate 
cancer and 30 cases of prostatic hyperplasia, similar to the findings reported by Effert 
(281). The prevalence of human papillomavirus infection in prostatic tissues in 
different reports may relate to the sexual behavior of the patients because sexual 
transmission is recognized as the most common route for dissemination of this virus. 
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VII. CONCLUSION 
The low incidence of prostatic carcinoma in Hong Kong is reflected by the low 
mortality in our male population due to this neoplasm and by the fact that only 14 of 
such cancer were newly diagnosed over a two-year period in the Prince of Wales 
Hospital, a 1,400-bed acute care institution. This study was based on 18 acinar type 
prostatic carcinoma, of which 77% were of intermediate histological grade, however 
72% were at the advanced stage D. ^ 
Molecular techniques used in the study of p53 suppressor gene in prostatic 
lesions included hybridization of DNA blots for alleilic loss around and at the p53 
gene, polymerase chain reaction-single stranded conformation polymorphism (PCR-
SSCP) and direct DNA sequencing for gene mutation. 
One single case of prostatic carcinoma demonstrated allelic loss of both 17pl3.3 
region around the p53 gene and Ha-ras oncogene, but no mutation of the p53 tumor 
suppressor gene was demonstrated in PCR-SSCP analysis. One other prostatic 
carcinoma was confirmed to have a p53 gene mutation in exon 5 by PCR-SSCP and 
direct DNA sequencing. Based on this study of a relatively small number of patients, 
the mutation of p53 suppressor gene in prostatic carcinoma is an uncommon event and 
unlikely to play a significant role in carcinogenesis in this tumor. 
Depending on the type of antibody used, immunoreactivity for p53 protein in 
prostatic carcinoma cells varied from 41% to 70%. The discrepancy between 
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immunohistochemistry and molecular techniques is readily apparent as only one case 
was confirmed to have p53 gene mutation and cannot be totally explained. Our 
findings support that commercial antibodies with specificity for mutant p53 protein 
may still demonstrate a cross-reactivity with denatured wild-type p53 protein as already 
reported. There is also growing evidence from the literature that non-mutational factors 
may play an important role in cellular accumulation or expression of p53 "mutant" 
protein, however these suspected factors remain to be identified. For the same reasons, 
direct gene analysis by molecular techniques are important in the study of p53 
suppressor gene. 
In cases of prostatic carcinoma with no demonstrable immunoreactivity for p53 
protein and mobility shift in SSCP analysis, contrasting to the findings in carcinoma 
of the cervix, we found no evidence that HPV infection was implicated in the negative 
findings. 
None of the 30 patients with prostatic hyperplasia demonstrated positive p53 
immunohistochemistry and allelic loss for p53 gene. However, p53 gene mutation were 
detected in two patients with prostatic hyperplasia, one of whom appeared to have 
germline mutation. The significance of these findings is uncertain, but none of these 
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APPENDIX - REAGENTS 
1. Acid Citrate Dextrose (ACD): containing 0.48g Citric acid (Sigma), 1.32g Sodium Citrate (Sigma) and 1.47g Glucose 
(Sigma) in 100 ml of ACD. 
2. TBS: contains 0.05M Tris-HCl (Sigma), O.IM NaCl (Sigma), pH 7.6. 
3. Avidin-biotin complex (1:100): For preparation of 1 ml of (1:100) Avidin-Biotin Complex, 10 ul of reagent A (Avidin) 
inO.OlM PBS, 0.15M NaCl, 15mM NaNj, pH 7.2 and 10 ul of reagent B (Biotinylated Horseradish Peroxidase) in O.OIM 
PBS, 0.15M NaCl, 15mM NaNj, pH 7.2 were mixed in 1ml of TBS for 30 minutes before use. 
^ 4. DAB solution: 30mg of 3,3'-Diaminobenzidine Tetrahydrochloride (Sigma) in 50 ml of TBS with 0.03 % hydrogen 
peroxide was filtered before use. 
5. Methyl Green Solution: Ig of Methyl Green (BDH) was dissolved in 200 ml of Acetrate Buffer pH 4.1 and then methyl 
violet was washed out completely by chloroform before use. 
6. Poly-L-lysine Solution: 0.01% of Poly-L-lysine (Sigma) in distilled water was prepared. 
7. lOmM Citrate Buffer pH 6.0: Prepared by dissolving 2.1g citric acid monohydrate (BDH) in distilled water to final 
volume of 1 liter after adjusting the pH to 6.0 with 2M NaOH (BDH). 
8. Harris ‘ Haematoxylin Solution: The 2.5g of Haematoxylin (BDH) was dissolved in 25ml of absolute alcohol (Merck) and 
was then added to the Potassium Alum(BDH) which had previously been dissolved in 500ml of warm distilled water in a 
• two-litre flask. The mixture was rapidly brought to the boil and 1.25g of mercuric oxide (BDH) was then added. After 
rapidly cooling by ice bath, 20 ml of glacial acetic acid was finally added. 
9. 1 OX PBS: (i.e. lOX Phosphate-buffered saline) contains 145mM NaCl (BDH), 12.4 mM NazHPCVllHzOCBDH)，2.5 
mM KHzPOaCBDH). The pH value was adjusted to 7.4 before autoclave. 
10. Digestion Buffer: containing lOOmM NaCl, lOmM Tris-HCl pH 8’ 25mM EDTA pH 8 (Sigma), 0.5% Sodium Dodecyl 
Sulfate (SDS)(BRL) and O.lmg/ml Proteinase K'®. 
11. Phenol/Chloroform/Isoamyl Alcohol Solution: perpared by mixing liquefied phenol (Redistilled Nucleic Acid Grade, 
BRL), Chloroform (BDH), and Isoamly Alcohol (Sigma) in a ratio of 25:24:1 (v/v/v) in 2 mM Tris-HCl pH8.0 for 3 hours 
in a dark bottle. The mixture was store at 4°C in the dark. 
12. 3M Sodium Acetate (NaAc)pH5.2: 4.08g Sodium Acetate.SHzO (Sigma) was dissolved in distilled water to a 1 litre after 
adjusting the pH to 5.2 with Glacial acetic acid (BDH) and then it was autoclaved. 
13. 70 % Ethanol: Absolute ethanol (Merck) and autoclaved double distilled water mixed in a ratio of 7:3. Freezed at -20°C. 
14. TEpH 7.5: contains O.lmM EDTA (Sigma) pH 7.5 and 1 mM Tris-HCl (Sigma) pH7.5 and then autoclaved. 




10 minutes. Stored at -20° C 
16. Proteinase K: 20 mg/ml Proteinase K (Sigma) in 10 mM Tris-HCl pH7.5. Stored at -20�C 
17. TEpH 8.0: contains 0.1 mM EDTA pH 8.0 and 1 mM Tris-HCl pH8.0. 
18. LB Broth: 10 g of Tryptone (OXOID), 5 g of Yeast Extract (OXOID), 10 g of Sodium Chloride (NaCl) in Distilled 
water.Adjustedto the pH to 7.5 with IM NaOH. Added distilled water to 1 litre and autoclaved. 
19. LB Agar Plate: Added 12 g Agar (OXOID) to 1 litre of LB broth. After autoclaved, LB agar plates were poured. 
20. Ampicillin: 25mg/ml solution of the sodium salt of ampicillin (Sigma) in distilled water. Sterilized by filtration and 
Stored at 
� 21. Choramphenicol: 34mg/ml solution of crystilline chloramphenicol (Sigma) in absolute ethanol. Stored at 
22. Buffer PI: contains 50mM Glucose, 25mMTris-HCl pH 8.0，lOmM EDTA pH 8.0. 
23. Buffer P2: contains 0.2N NaOH and 0.1 % SDS. 
24. Buffer P3: i.e. 5M potassium acetate (KCl) pH 4.8, prepared by mixing 60 ml of 5M Potassium acetate (BDH) with 
11.5 ml of Glacial Acetic Acid (BDH) and 28.5 ml of Distilled water. 
25. Qiagen>Plasmid<kit: involves Qiagen column, QB Buffer^, QC Buffer", and QF Buffer^. 
26. QB Buffer. 750mM NaCl, 50mM MOPS, 15% ethanol and 0.15% Triton X-100, pH7.0. 
27. QC Buffer. l.OM NaCl, 50mM MOPS and 15% ethanol, pH7.0. 
28. QF Buffer: 1.25M NaCl, 50mM MOPS and 15 ethanol, pH 8.2. 
29. 0.8 % Agarose Gel: Dissolved 1.2 g of Agarose Gel (Standard, Sigma) in 150ml IXTBE^' by microwave oven heating. 
Poured into gel cast (BRL). 
30. Ethidium Bromide (lOmg/ml): 0.2 g of Ethidium Bromide (Sigma)was dissolved in 20 ml Distilled water and then stored 
at r c in dark. 
31. IX TBE: contains 0.05M Tris-HCl, 0.05M Boric Acid (BDH), and 2.5mM EDTA. The pH value was adjusted to 8.0 
before autoclaved. 
32. Size Marker: Lambda DNA/Hind III fragments in TE pH 7.4 (BRL). 
33. Megaprime DNA Lebelling System: involves Primer Solution拟，Megaprime Reaction Buffer]! and Enzyme Solution站. 
34. Primer Solution: Random nonamer primers in an aqueous solution. 
35. Megaprime Reaction Buffer. dATP, dGTP and dTTP in concentrated reaction buffer containing Tris-HCl pH 7.5， 
magnesium chloride and 2-mercaptoethanol. 
36. Enzyme Solution: 1 unit/ul DNA Polymerase I "Klenow" fragment in 50mM potassium Phosphate pH 6.5, lOmM 2-
mercapatoethanol and 50% glycerol. 




of 1 litre after adjusting the pH to 8.0 with NaOH and then it was autoclaved. 
38. STE: contains O.IM NaCl, 0.05M Tris-HCl pH7.5 and ImM EDTA pH 7.4; and then autoclaved. 
39. Denaturation Solution: contains 1.5M NaCl and 0.5M NaOH. 
40. Neutralization Solution: 1.5M NaCl and IM Tris-HCl pH 8.0. 
41. 20X SSC: contain 3M NaCl, 0.3M NaAc pH 8.0. 
42. Prehybridization Solution: contains 5X SSPE*(Sigma), 50% Formamide**(Sigma), 5X Denhardt's Solution***, 0.5% 
SDS and 150ug/ml denatured sonicated Salmon Sperm DNA****. 
*20X SSPE-- 3M NaCl, 0.2M NaHzPCVHaO and 20mM EDTA. The pH value was adjusted to 7.4 with IM 
� NaOH. . 
**100% Deionized Formamide- prepared by stirring 100ml of formamide and 4 g of Amberlite MB-1 (Sigma) 
for 2 hours in a dark bottle. After removing the ion-exchange resin by filtration through Whatman No.l paper, it was stored 
at -20OC. 
***100X Denhardt's Solution- 20mg/ml Polyvinyl pyrollidone (Sigma), 20mg/ml Ficoll-400 (Pharmacia) and 
20mg/ml Bovine Serum Albumin (Sigma) in autoclaved double distilled water. Sterilized by millipore (Millipore) filtration. 
****Denatured Sonicated Salmon Sperm DNA- DNA was denatured by boiling for 10 minutes and chilled on 
icefor Sminutes. 
43. Hybridization Solution: Denatured radioactive labelled DNA probe by boiling was added into and immediately chilling 
on ice.was added into Prehybridization Solution*� 
44. 5'-End Labelling Kit: involves T4 Polynucleotide Kinase恥 and Phosphorylation Reaction Buffer'*'. 
45. T4 Polynucleotide Kinase: 10 units/ul T4 polynucleotide kinase was provided. 
46. Phosphorylation Reaction Buffer: lOX Phosphorylation reaction buffer was provided. 
47. GeneAmpTMPolymerase Chain Reaction Kit: involves lOX PGR Buffer^，Deoxyribonucleotide triphosphates (dNTPs) 
mixture^ and AmpliTaq™DNA Polymerase^'. 
48. lOX PCR Buffer: 500mM KCl and lOOmM Tris-HCl pH 8.3. 
49. 2.5mM Deoxyribonucleotide triphosphates (dNTPs) mixture: contains 2.5mM each dATP, dGTP, dCTP and dTTP. 
50. AmpliTaq™ DNA Polymerase: 5 units/ul of AmpliTaq™r>NA polymerase was provided. 
51. Loading Buffer: 95% Formamide, 20mM EDTA, 0.05% Bromophenol Blue (Sigma) and 0.05% Xylene Cyanol FF 
(Sigma). 
52. 3% Glycerol: Prepared by 50% Glycerol stock solution which is onefold dilution of glycerol (Sigma) with distilled 
water. Autoclaved. 
53. Maq™Cycle-Sequencing Kit: involves Reaction Buffer", ATaq version 2.0 solution免，Termination Mix幻 and Stop 
170 '彳 
Solution^®. 
54. Reaction Buffer: (Concentrated) 260mM Tris-Hcl ph9.5, 65mM MgCl:. 
55. LTaq version 2.0 Solution: 32 units/ul ATaq version 2.0 DNA Polymerase was mixed at a ratio of 1:7 with ATaq 
version 2.0 DNA Polymerase Dilution Buffer containing lOmM Tris-HCl pH 8.0，ImM 2-mercaptoethanol, 0.5% Tween'-
20，0.5 Nonidet* P-40. 
56. Termination Mix: involves 4 types of Termination Mix. They are ddATP Termination Mix*, ddGTP Termination 
Mix**，ddCTP Termination Mix***，and ddTTP Termination Mix****. 
*ddATP Termination Mix-15uM each dATP, dGTP, dCTP and dTTP; 300uM ddATP. 
"ddGTP Termination Mix-15uM each dATP, dGTP, dCTP and dTTP; 22.5uM ddGTP. 
***ddCTP Termination Mix-15uM each dATP, dGTP, dCTP and dTTP; 75uM ddCTP. 
****ddTTP Termination Mix--15uM each dATP, dGTP, dCTP and dTTP; 450uM ddTTP. 
57. Stop Solution: 95% formamide, 20uM EDTA, 0.05% Bromophenol Blue, 0.05% Xylene Cyanol FF. 
58. 8 % Sequencing Gel: 6.0 g of Acrylamide, 0.20 g of N,N'-methylenebisacrylamide and 31.5 g of urea (BRL) were 
dissloved in 75 ml final volume of IX TBE. Following addition of 425 ul of 10% Ammonium persulfate (BRL), the solution 
was degased and finally 26 ul of N,N,N',N'-Tetramethylethylenediamine (TEMED)(BRL) was added just before use. 
59. GeneAmp™-Polymerase Chain Reaction Kit: involves lOXPCR buffer, 25mM MgCl� and 2.5mM dNTPs. 
60. 50mM Potassium Chloride: Presented in lOX PCR buffer. 
61. lOmM Tris-HCl pH 8.3: Presented in lOX PCR buffer. 
62. 7mM Magnesium Chloride (MgCl�:): Prepared by addition of 14 ul of 25mM MgClz for 50 ul total PCR reaction 
mixture. 
63. 400 uMDeoxynuleotide Triphosphates (dNTPs): Prepared by addition of 8 ul of 2.5mM which contained 2.5mM each 
dATP, dGTP, dCTP and dTTP. 
64. AmpliTaq™Polymerase: 5 units/ul of AmpliTaq™D^K polymerase was provided. 
65. Prehybridization solution for detection of HPVs: contain 5XSSC, 75 mM EDTA pH 8.0，5X Denhardt's solution, 0.5 % 
SDS and 5ug/ml denatured Salmon Sperm DNA. 
66. Hybridization solution for detection ofHPVs: is 15ml prehybridization solution plus 12.5 pmloe radiolabeled oligoprobe. 
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